IRIS: Difference between revisions

From Opasnet
Jump to navigation Jump to search
m (unfinished)
(technical edits)
 
(9 intermediate revisions by 4 users not shown)
Line 41: Line 41:
  http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)
  http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)


===Oral RfDs===
{{defend|# |Tämähän alkaa olla oikein hyvä! Alla vielä muutamia kommentteja.|--[[User:Jouni|Jouni]] 20:34, 28 June 2012 (EEST)}}


Oral RfDs were scrapped as an example (chemical starting with A) on Jan 4, 2012.
* Tulokset on tässä kirjoitettu muotoon 3.4x10-3. Joko interpret-funktiota on päivitettävä siten, että se ymmärtää tämän, tai sitten kaikki näiden taulukoiden tulokset pitää muuttaa muotoon 3.4e-3 (jonka R ymmärtää oikein, kun käytetään as.numericia). Tuntuu, että interpretin päivitys olisi parempi vaihtoehto.
* Yksiköt pitäisi muuttaa tietokoneelle ymmärrettäväksi. Vaihtoehtoja: a) [[Unit conversions]] -sivulle lisätään kaikki tässä esiintyvät uudet yksiköt, niin että niille saadaan muunnosohjeet (esim. mg /kg-day &rarr; mg /kg /d tai per µg /m<sup>3</sup> &rarr; m3 /µg. b) Kaikki yksiköt tällä sivulla muutetaan tuohon standardimuotoon. Mikä tuntuisi järkevältä?
 
 
{{attack|# |Jos jossakin taulukossa joka rivillä on sama yksikkö, koko saraketta ei tarvita vaan riittää yksikön ilmoittaminen osoiterivillä.|--[[User:Jouni|Jouni]] 20:34, 28 June 2012 (EEST)}}


{{attack|# |Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä.|--[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}
{{attack|# |Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä.|--[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}
Line 52: Line 56:
|3 = --[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}
|3 = --[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}


<t2b index = "Substance,Observation type" locations = "CASRN,Critical Effact(s),Unit,Oral RfD,Type of RfD,Point of Departure(s)*,Overall Confidence,IRIS identifier" unit = "mg /kg-day">
==See also==
Acenaphthene|83-32-9| Hepatotoxicity|mg /kg-day|6 x10-2|NOAEL|175|Low|0442
Acenaphthylene|208-96-8|Not Assessed under the IRIS program||||||0443
Acephate|30560-19-1|Inhibition of brain ChE|mg /kg-day|4 x10-3|LEL|0.12|High|0354
Acetaldehyde|75-07-0|Not Assessed under the IRIS program||||||0290
Acetochlor|34256-82-1|Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males|mg /kg-day|2 x10-2|NOAEL|2 mg/kg-day|High|0521
Acetone|67-64-1|Nephropathy|mg /kg-day|0.9|NOAEL|900|Medium|0128
Acetonitrile|75-05-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0205
Acetophenone|98-86-2|General toxicity|mg /kg-day|1 x10-1|NOAEL|423|Low|0321
Acetyl chloride|75-36-5|Not Assessed under the IRIS program||||||0518
Acifluorfen, sodium|62476-59-9|Mortality and kidney lesions|mg /kg-day|1.3 x10-2|NOEL|1.25|Medium|0192
Acrolein|107-02-8|Decreased survival|mg /kg-day|5 x10-4|NOAEL|0.05|Medium/High|0364
Acrylamide|79-06-1|Degenerative nerve changes|mg /kg-day|0.002|HED (BMDL)|0.053|Medium/High|0286
Acrylic acid|79-10-7|Reduced pup weight|mg /kg-day|5 x10-1|NOAEL|53|High|0002
Acrylonitrile|107-13-1|Not Assessed under the IRIS program||||||0206
Adiponitrile|111-69-3|Not Assessed under the IRIS program||||||0515
Alachlor|15972-60-8|Hemosiderosis, hemolytic anemia|mg /kg-day|1 x10-2|NOAEL|1|High|0129
Alar|1596-84-5|No adverse effects|mg /kg-day|1.5 x10-1|NOEL|15|Low|0287
Aldicarb|116-06-3|Sweating as clinical sign of AChe inhibition (other effect: Clinical signs and symptoms of acetylcholinesterase inhibition including sweating, pinpoint pupils, leg weakness, and other effects Nausea, diarrhea, and other signs and symptoms)|mg /kg-day|1 x10-3|NOAEL|0.01|Medium|0003
Aldicarb sulfone|1646-88-4|Brain ChE inhibition in females|mg /kg-day|1 x10-3|NOAEL|0.11|Medium|0312
Aldrin|309-00-2|Liver toxicity|mg /kg-day|3 x10-5|LOAEL|0.025|Medium|0130
Ally|74223-64-6|Decreased body weight|mg /kg-day|2.5 x10-1|NOEL|25|High|0288
Allyl alcohol|107-18-6|Impaired renal function and increased liver and kidney weights|mg /kg-day|5 x10-3|NOEL|4.8|Low|0004
Allyl chloride|107-05-1|Not Assessed under the IRIS program||||||0387
Aluminum phosphide|20859-73-8|Body weight and clinical parameters|mg /kg-day|4 x10-4|NOAEL|0.043|Medium|0005
Amdro|67485-29-4|Increased organ weights|mg /kg-day|3 x10-4|NOEL|0.33|High|0207
Ametryn|834-12-8|Liver toxicity|mg /kg-day|9 x10-3|NOEL|8.6|Low|0208
4-Aminopyridine|504-24-5|Not Assessed under the IRIS program||||||0440
Amitraz|33089-61-1|Increased mean blood sugar concentration; slight hypothermia|mg /kg-day|2.5 x10-3|NOEL|0.25|Medium|0334
Ammonia|7664-41-7|Not Assessed under the IRIS program||||||0422
Ammonium acetate|631-61-8|Not Assessed under the IRIS program||||||0517
Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program||||||0516
Ammonium sulfamate|7773-06-0|Decrease in body weight|mg /kg-day|2 x10-1|NOEL|214.3|Low|0007
Aniline|62-53-3|Not Assessed under the IRIS program||||||0350
ortho-Anisidine|90-04-0|Not Assessed under the IRIS program||||||0610
Anthracene|120-12-7|No observed effects|mg /kg-day|3 x10-1|NOEL|1000|Low|0434
Antimony|7440-36-0|Longevity, blood glucose, and cholesterol|mg /kg-day|4 x10-4|LOAEL|0.35|Low|0006
Antimony trioxide|1309-64-4|Not Assessed under the IRIS program||||||0676
Apollo|74115-24-5|Liver effects; organ weight changes|mg /kg-day|1.3 x10-2|NOEL|1.25|High|0008
Aramite|140-57-8|Not Assessed under the IRIS program||||||0473
Aroclor 1016|12674-11-2|Reduced birth weights|mg /kg-day|7 x10-5|NOAEL|0.007|Medium|0462
Aroclor 1248|12672-29-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0649
Aroclor 1254|11097-69-1|Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes|mg /kg-day|2 x10-5|LOAEL|0.005|Medium|0389
Arsenic, inorganic|7440-38-2|Hyperpigmentation, keratosis and possible vascular complications|mg /kg-day|3 x10-4|NOAEL|0.0008|Medium|0278
Arsine|7784-42-1|Not Assessed under the IRIS program||||||0672
Asbestos|1332-21-4|Not Assessed under the IRIS program||||||0371
Assure|76578-14-8|Liver cell enlargement|mg /kg-day|9 x10-3|NOEL|0.9|High|0335
Asulam|3337-71-1|Lower ovarian weight, lower liver/body weight|mg /kg-day|5 x10-2|LEL|50|Medium|0284
Atrazine|1912-24-9|Decreased body weight gain (other effect: Cardiac toxicity and moderate-to-severe dilation of the right atrium)|mg /kg-day|3.5 x10-2|NOAEL|3.5|High|0209
Avermectin B1|65195-55-3|Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth|mg /kg-day|4 x10-4|NOEL|0.12|High|0381
Azobenzene|103-33-3|Not Assessed under the IRIS program||||||0351
Barium and Compounds|7440-39-3|Nephropathy|mg /kg-day|0.2|BMDL05|63|Medium|0010
Barium cyanide|542-62-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0009
Baygon|114-26-1|Mild cholinergic symptoms and RBD ChE inhibition|mg /kg-day|4 x10-3|LEL|0.36|Medium|0210
Bayleton|43121-43-3|Decreased body weight gain, erythrocyte count and hemoglobin level|mg /kg-day|3 x10-2|NOEL|2.5|High|0131
Baythroid|68359-37-5|Decreased body weights in males, inflammatory foci in kidneys of females|mg /kg-day|2.5 x10-2|NOEL|2.5|High|0132
Benefin|1861-40-1|Depressed erythrocyte counts|mg /kg-day|3 x10-1|NOAEL|25|Medium|0133
Benomyl|17804-35-2|Decreased pup weanling weights|mg /kg-day|5 x10-2|NOEL|5 mg/kg-day|High|0011
Bentazon (Basagran)|25057-89-0|Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs (other effect: Dose-related increase in red areas (presumed blood) in feces; coagulation defect)|mg /kg-day|3.0 x10-2|NOAEL (ADJ)|3.2|Medium|0134
Benz[a]anthracene|56-55-3|Not Assessed under the IRIS program||||||0454
Benzaldehyde|100-52-7|Forestomach lesions, kidney toxicity|mg /kg-day|1 x10-1|NOEL|143|Low|0332
Benzene|71-43-2|Decreased lymphocyte count|mg /kg-day|4.0 x10-3|BMDL|1.2|Medium|0276
Benzidine|92-87-5|Brain cell vacuolization; liver cell alterations in females|mg /kg-day|3 x10-3|LOAEL|2.7|Medium|0135
</t2b>
 
===Inhalation RfCs===
 
<t2b index = "Substance,Observation type" locations = "CASRN,Critical Effact(s),Unit,Inhalation RfC,Type of RfC,Point of Departure(s)*,Overall Confidence,IRIS identifier" unit = "mg /m<sup>3</sup>">
Acenaphthene|83-32-9|Not Assessed under the IRIS program.||||||
Acenaphthylene|208-96-8|Not Assessed under the IRIS program.||||||
Acephate|30560-19-1|Not Assessed under the IRIS program.||||||
Acetaldehyde|75-07-0|Degeneration of olfactory epithelium|mg /m<sup>3</sup>|9x10<sup>-3</sup>|NOAEL (HEC)|8.7|Low|0290
Acetochlor|34256-82-1|Not Assessed under the IRIS program.||||||
Acetone|67-64-1|Not Assessed under the IRIS program.||||||
Acetonitrile|75-05-8|Not Assessed under the IRIS program.||||||
Acetophenone|98-86-2|Mortality|mg /m<sup>3</sup>|6x10<sup>-2</sup>|NOAEL (HEC)|60|Medium|0205
Acetyl chloride|75-36-5|Not Assessed under the IRIS program.||||||
Acifluorfen, sodium|62476-59-9|Not Assessed under the IRIS program.||||||
Acrolein|107-02-8|Nasal lesions|mg /m<sup>3</sup>|2x10<sup>-5</sup>|LOAEL (HEC)|0.02|Medium|0364
Acrylamide|79-06-1|Degenerative nerve changes|mg /m<sup>3</sup>|0.006|HEC (BMDL)|0.18|Medium|0286
Acrylic acid|79-10-7|Degeneration of the nasal olfactory epithelium|mg /m<sup>3</sup>|1x10<sup>-3</sup>|LOAEL (HEC)|0.33|Medium|0002
Acrylonitrile|107-13-1|Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells|mg /m<sup>3</sup>|2x10<sup>-3</sup>|LOAEL (HEC)|1.9|Medium|0206
Adiponitrile|111-69-3|Not Assessed under the IRIS program.||||||
Alachlor|15972-60-8|Not Assessed under the IRIS program.||||||
Alar|1596-84-5|Not Assessed under the IRIS program.||||||
Aldicarb|116-06-3|Not Assessed under the IRIS program.||||||
Aldicarb sulfone|1646-88-4|Not Assessed under the IRIS program.||||||
Aldrin|309-00-2|Not Assessed under the IRIS program.||||||
Ally|74223-64-6|Not Assessed under the IRIS program.||||||
Allyl alcohol|107-18-6|Not Assessed under the IRIS program.||||||
Allyl chloride|107-05-1|Functional and histological peripheral neurotoxicity|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|3.6|Low|0387
Aluminum phosphide|20859-73-8|Not Assessed under the IRIS program.||||||
Amdro|67485-29-4|Not Assessed under the IRIS program.||||||
Ametryn|834-12-8|Not Assessed under the IRIS program.||||||
4-Aminopyridine|504-24-5|Not Assessed under the IRIS program.||||||
Amitraz|33089-61-1|Not Assessed under the IRIS program.||||||
Ammonia|7664-41-7|Not Assessed under the IRIS program.||||||
Ammonium acetate|631-61-8|Not Assessed under the IRIS program.||||||
Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program.||||||
Ammonium sulfamate|7773-06-0|Not Assessed under the IRIS program.||||||
Aniline|62-53-3|Lack of toxicity (other effect: Mild spleen toxicity )|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|3.4|Low|0350
ortho-Anisidine|90-04-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0610
Anthracene|120-12-7|Not Assessed under the IRIS program.||||||
Antimony|7440-36-0|Not Assessed under the IRIS program.||||||
Antimony trioxide|1309-64-4|Pulmonary toxicity, chronic interstitial inflammation|mg /m<sup>3</sup>|2x10<sup>-4</sup>|BMC<sub>10</sub> (HEC)|0.074|Medium|0676
Apollo|74115-24-5|Not Assessed under the IRIS program.||||||
Aramite|140-57-8|Not Assessed under the IRIS program.||||||
Aroclor 1016|12674-11-2|Not Assessed under the IRIS program.||||||
Aroclor 1248|12672-29-6|Not Assessed under the IRIS program.||||||
Aroclor 1254|11097-69-1|Not Assessed under the IRIS program.||||||
Arsenic, inorganic|7440-38-2|Not Assessed under the IRIS program.||||||
Arsine|7784-42-1|Increased hemolysis, abnormal RBC morphology, and increased spleen weight (other effect: Increased hemolysis, increased spleen weight, and impaired compensatory erythropoiesis)|mg /m<sup>3</sup>|5x10<sup>-5</sup>|NOAEL (HEC)|0.014|Medium|0672
Asbestos|1332-21-4|Not Assessed under the IRIS program.||||||
Assure|76578-14-8|Not Assessed under the IRIS program.||||||
Asulam||Not Assessed under the IRIS program.||||||
Atrazine||Not Assessed under the IRIS program.||||||
Avermectin B1||Not Assessed under the IRIS program.||||||
Azobenzene||Not Assessed under the IRIS program.||||||
Barium and Compounds||Not Assessed under the IRIS program.||||||
Barium cyanide||Not Assessed under the IRIS program.||||||
Baygon||Not Assessed under the IRIS program.||||||
Bayleton||Not Assessed under the IRIS program.||||||
Baythroid||Not Assessed under the IRIS program.||||||
Benefin||Not Assessed under the IRIS program.||||||
Benomyl||Not Assessed under the IRIS program.||||||
Bentazon (Basagran)||Not Assessed under the IRIS program.||||||
Benz[a]anthracene||Not Assessed under the IRIS program.||||||
Benzaldehyde||Not Assessed under the IRIS program.||||||
Benzene|71-43-2|Decreased lymphocyte count|mg /m<sup>3</sup>|3x10<sup>-2</sup>|BMCL|8.2|Medium|0276
Benzidine|92-87-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0135
Benzo[a]pyrene (BaP)||Not Assessed under the IRIS program.||||||
Benzo[b]fluoranthene||Not Assessed under the IRIS program.||||||
Benzo[g,h,i]perylene||Not Assessed under the IRIS program.||||||
Benzo[k]fluoranthene||Not Assessed under the IRIS program.||||||
Benzoic acid||Not Assessed under the IRIS program.||||||
Benzotrichloride||Not Assessed under the IRIS program.||||||
Benzyl chloride|100-44-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0393
Beryllium and compounds|7440-41-7|Beryllium sensitization and progression to CBD|mg /m<sup>3</sup>|2x10<sup>-5</sup>|LOAEL (HEC)|0.0002|Medium|0012
Bidrin||Not Assessed under the IRIS program.||||||
Biphenthrin||Not Assessed under the IRIS program.||||||
1,1-Biphenyl|92-52-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0013
Bis(2-chloro-1-methylethyl) ether||Not Assessed under the IRIS program.||||||
Bis(2-chloroethoxy)methane||Not Assessed under the IRIS program.||||||
Bis(chloroethyl)ether (BCEE)|111-44-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0137
Bis(chloromethyl)ether (BCME)|542-88-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0375
Bisphenol A.|80-05-7|Not Assessed under the IRIS program.||||||
Boron and Compounds||Information reviewed but value not estimated. Refer to IRIS Summary.||||||0410
Bromate|15541-45-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1002
Brominated dibenzofurans|NA|Not Assessed under the IRIS program.||||||
Bromobenzene|108-86-1|Hepatocellular cytomegaly in female B6C3F1 mice|mg /m<sup>3</sup>|6x10<sup>-2</sup>|BMCL<sub>10</sub> (HEC)|63|Low/Medium|1020
Bromochloromethane||Not Assessed under the IRIS program.||||||
Bromodichloromethane||Not Assessed under the IRIS program.||||||
p-Bromodiphenyl ether||Not Assessed under the IRIS program.||||||
Bromoform|75-25-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0214
Bromomethane|74-83-9|Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity|mg /m<sup>3</sup>|5x10<sup>-3</sup>|LOAEL (HEC)|0.48|High|0015
Bromotrichloromethane||Not Assessed under the IRIS program.||||||
Bromoxynil||Not Assessed under the IRIS program.||||||
Bromoxynil octanoate||Not Assessed under the IRIS program.||||||
1,3-Butadiene|106-99-0|Ovarian atrophy|mg /m<sup>3</sup>|2x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|1.98|Medium|0139
n-Butanol||Not Assessed under the IRIS program.||||||
Butyl benzyl phthalate||Not Assessed under the IRIS program.||||||
Butylate||Not Assessed under the IRIS program.||||||
t-Butylchloride||Not Assessed under the IRIS program.||||||
Butylphthalyl butylglycolate (BPBG)||Not Assessed under the IRIS program.||||||
Cacodylic acid||Not Assessed under the IRIS program.||||||
Cadmium||Not Assessed under the IRIS program.||||||
Calcium cyanide||Not Assessed under the IRIS program.||||||
Caprolactam|105-60-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0357
Captafol||Not Assessed under the IRIS program.||||||
Captan||Not Assessed under the IRIS program.||||||
Carbaryl|63-25-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0019
Carbofuran||Not Assessed under the IRIS program.||||||
Carbon disulfide|75-15-0|Peripheral nervous system dysfunction|mg /m<sup>3</sup>|7x10<sup>-1</sup>|BMC<sub>10</sub> (HEC)|19.7|Medium|0217
Carbon tetrachloride|56-23-5|Not Assessed under the IRIS program.|Fatty changes in the liver|mg /m<sup>3</sup>|0.1|BMCL<sub>10</sub> (HEC)|14.3|0020
Carbonyl sulfide|463-58-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0617
Carbosulfan||Not Assessed under the IRIS program.||||||
Carboxin||Not Assessed under the IRIS program.||||||
Cerium Oxide and Cerium Compounds|1306-38-3|Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats|mg /m<sup>3</sup>|9x10<sup>-4</sup>|BMCL (HEC)|0.86|Low|1018
Chloral hydrate||Not Assessed under the IRIS program.||||||
Chloramben||Not Assessed under the IRIS program.||||||
Chlordane (Technical)|12789-03-6|Hepatic effects|mg /m<sup>3</sup>|7x10<sup>-4</sup>|NOAEL (HEC)|0.65|Low|0142
Chlordecone (Kepone)|143-50-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1017
Chlorimuron-ethyl||Not Assessed under the IRIS program.||||||
Chlorine||Not Assessed under the IRIS program.||||||
Chlorine cyanide||Not Assessed under the IRIS program.||||||
Chlorine dioxide|10049-04-4|Vascular congestion and peribronchial edema (other effect: Hemorrhagic alveoli and congested capillaries in the lungs)|mg /m<sup>3</sup>|2x10<sup>-4</sup>|LOAEL (HEC)|0.64|Low|0496
Chlorite (sodium salt)|7758-19-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0648
1-Chloro-1,1-difluoroethane|75-68-3|No adverse effects|mg /m<sup>3</sup>|5x10<sup>1</sup>|NOAEL (HEC)|14710|Medium|0661
2-Chloroacetophenone|532-27-4|Squamous hyperplasia of the nasal respiratory epithelium|mg /m<sup>3</sup>|3x10<sup>-5</sup>|LOAEL (HEC)|0.03|Low|0537
p-Chloroaniline||Not Assessed under the IRIS program.||||||
Chlorobenzene||Not Assessed under the IRIS program.||||||
Chlorobenzilate||Not Assessed under the IRIS program.||||||
1-Chlorobutane||Not Assessed under the IRIS program.||||||
2-Chlorobutane||Not Assessed under the IRIS program.||||||
Chlorocyclopentadiene||Not Assessed under the IRIS program.||||||
Chlorodifluoromethane|75-45-6|Increased kidney, adrenal and pituitary weights (other effect: Reduced maternal weight gain)|mg /m<sup>3</sup>|5x10<sup>1</sup>|NOAEL (HEC)|5260|Medium|0657
Chloroform||Not Assessed under the IRIS program.||||||
Chloromethyl methyl ether (CMME)||Not Assessed under the IRIS program.||||||
beta-Chloronaphthalene||Not Assessed under the IRIS program.||||||
2-Chlorophenol||Not Assessed under the IRIS program.||||||
p-Chlorophenyl methyl sulfide||Not Assessed under the IRIS program.||||||
p-Chlorophenyl methyl sulfone||Not Assessed under the IRIS program.||||||
p-Chlorophenyl methyl sulfoxide||Not Assessed under the IRIS program.||||||
Chloroprene|126-99-8|Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively|mg /m<sup>3</sup>|2x10<sup>-2</sup>|BMDL (HEC)|2|Medium/High|1021
Chlorothalonil||Not Assessed under the IRIS program.||||||
o-Chlorotoluene||Not Assessed under the IRIS program.||||||
Chlorpropham||Not Assessed under the IRIS program.||||||
Chlorpyrifos||Not Assessed under the IRIS program.||||||
Chlorsulfuron||Not Assessed under the IRIS program.||||||
Chromium(III), insoluble salts|16065-83-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0028
Chromium(VI) (Chromic acid mists and dissolved Cr(VI) aerosols)|18540-29-9|Nasal septum atrophy|mg /m<sup>3</sup>|8x10<sup>-6</sup>|LOAEL (ADJ)|0.000714|Low|0144
Chromium(VI) (Cr(VI) particulates)|18540-29-9|Lactate dehydrogenase in bronchioalveolar lavage fluid||1x10<sup>-4</sup>|BMC<sub>10</sub> (ADJ)|0.034|Medium|0144
Chrysene||Not Assessed under the IRIS program.||||||
Coke oven emissions||Not Assessed under the IRIS program.||||||
Copper||Not Assessed under the IRIS program.||||||
Copper cyanide||Not Assessed under the IRIS program.||||||
Creosote||Not Assessed under the IRIS program.||||||
Crotonaldehyde||Not Assessed under the IRIS program.||||||
Cumene|98-82-8|Increased kidney weights in female rats and adrenal weights in male and female rats|mg /m<sup>3</sup>|4x10<sup>-1</sup>|NOAEL (HEC)|435|Medium|0306
Cyanazine||Not Assessed under the IRIS program.||||||
Cyanide, free||Not Assessed under the IRIS program.||||||
Cyanogen||Not Assessed under the IRIS program.||||||
Cyanogen bromide||Not Assessed under the IRIS program.||||||
Cyclohexane|110-82-7|Reduced pup weights in the F1 and F2 generations|mg /m<sup>3</sup>|6|BMCL<sub>1sd</sub> (HEC)|1822|Low/Medium|1005
Cyclohexanone||Not Assessed under the IRIS program.||||||
Cyclohexylamine||Not Assessed under the IRIS program.||||||
Cyhalothrin/Karate||Not Assessed under the IRIS program.||||||
Cypermethrin||Not Assessed under the IRIS program.||||||
Cyromazine||Not Assessed under the IRIS program.||||||
Dacthal||Not Assessed under the IRIS program.||||||
Dalapon, sodium salt||Not Assessed under the IRIS program.||||||
Danitol||Not Assessed under the IRIS program.||||||
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)|1163-19-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0035
Demeton||Not Assessed under the IRIS program.||||||
Di (2-ethylhexyl)phthalate (DEHP)||Not Assessed under the IRIS program.||||||
Di(2-ethylhexyl)adipate||Not Assessed under the IRIS program.||||||
2,4-Diaminotoluene|95-80-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0536
Diazomethane|334-88-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0616
Dibenz[a,h]anthracene||Not Assessed under the IRIS program.||||||
Dibenzofuran||Not Assessed under the IRIS program.||||||
1,2-Dibromo-3-chloropropane (DBCP)|96-12-8|Testicular effects|mg /m<sup>3</sup>|2x10<sup>-4</sup>|NOAEL (HEC)|0.17|Medium|0414
1,4-Dibromobenzene||Not Assessed under the IRIS program.||||||
Dibromochloromethane||Not Assessed under the IRIS program.||||||
Dibromodichloromethane||Not Assessed under the IRIS program.||||||
p,p'-Dibromodiphenyl ether||Not Assessed under the IRIS program.||||||
1,2-Dibromoethane|106-93-4|Nasal inflammation|mg /m<sup>3</sup>|9x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|2.8|Medium|0361
Dibutyl phthalate|84-74-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0038
Dicamba||Not Assessed under the IRIS program.||||||
Dichloroacetic acid|79-43-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0654
1,3-Dichlorobenzene||Not Assessed under the IRIS program.||||||
1,4-Dichlorobenzene|106-46-7|Increased liver weights in P1 males|mg /m<sup>3</sup>|8x10<sup>-1</sup>|NOAEL (HEC)|75|Medium|0552
1,2-Dichlorobenzene||Not Assessed under the IRIS program.||||||
3,3'-Dichlorobenzidine|91-94-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0504
Dichlorodifluoromethane||Not Assessed under the IRIS program.||||||
p,p'-Dichlorodiphenyl dichloroethane (DDD)||Not Assessed under the IRIS program.||||||
p,p'-Dichlorodiphenyldichloroethylene (DDE)||Not Assessed under the IRIS program.||||||
p,p'-Dichlorodiphenyltrichloroethane (DDT)||Not Assessed under the IRIS program.||||||
1,2-Dichloroethane||Not Assessed under the IRIS program.||||||
1,1-Dichloroethane||Not Assessed under the IRIS program.||||||
trans-1,2-Dichloroethylene|156-60-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0314
cis-1,2-Dichloroethylene|156-59-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0418
1,1-Dichloroethylene (1,1-DCE)|75-35-4|Liver toxicity (fatty change)|mg /m<sup>3</sup>|2x10<sup>-1</sup>|BMCL<sub>10</sub> (HEC)|6.9|Medium|0039
Dichloromethane|75-09-2|Hepatic effects (hepatic vacuolation)|mg /m<sup>3</sup>|6x10<sup>-1</sup>|BMDL<sub>10</sub> (HEC)|17.2|Medium/High|0070
2,4-Dichlorophenol||Not Assessed under the IRIS program.||||||
4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB)||Not Assessed under the IRIS program.||||||
2,4-Dichlorophenoxyacetic acid (2,4-D)||Not Assessed under the IRIS program.||||||
1,2-Dichloropropane|78-87-5|Hyperplasia of the nasal mucosa|mg /m<sup>3</sup>|4x10<sup>-3</sup>|LOAEL (HEC)|1.3|Medium|0601
2,3-Dichloropropanol||Not Assessed under the IRIS program.||||||
1,3-Dichloropropene|542-75-6|Hypertrophy/ hyperplasia of the nasal respiratory epithelium|mg /m<sup>3</sup>|2x10<sup>-2</sup>|BMCL<sub>10</sub> (HEC)|0.72|High|0224
Dichlorvos|62-73-7|Decreased brain cholinesterase activity|mg /m<sup>3</sup>|5x10<sup>-4</sup>|NOAEL (HEC)|0.05|Medium|0151
Dicofol||Not Assessed under the IRIS program.||||||
Dieldrin||Not Assessed under the IRIS program.||||||
Diesel engine exhaust|NA|Pulmonary inflammation and histopathology|mg /m<sup>3</sup>|5x10<sup>-3</sup>|NOAEL (HEC)|0.144|Medium|0642
Diethyl phthalate||Not Assessed under the IRIS program.||||||
Diethyl sulfate|64-67-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0615
Diethyl-p-nitrophenylphosphate||Not Assessed under the IRIS program.||||||
Diethylene glycol dinitrate (DEGDN)||Not Assessed under the IRIS program.||||||
Difenzoquat||Not Assessed under the IRIS program.||||||
Diflubenzuron||Not Assessed under the IRIS program.||||||
1,1-Difluoroethane|75-37-6|No adverse effects observed|mg /m<sup>3</sup>|4x10<sup>1</sup>|NOAEL (HEC)|12051|Medium|0665
Diisopropyl methylphosphonate (DIMP)||Not Assessed under the IRIS program.||||||
Dimethipin||Not Assessed under the IRIS program.||||||
Dimethoate||Not Assessed under the IRIS program.||||||
Dimethyl phthalate|131-11-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0353
Dimethyl sulfate|77-78-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0365
Dimethyl terephthalate (DMT)||Not Assessed under the IRIS program.||||||
Dimethylamine|124-40-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0228
N-N-Dimethylaniline||Not Assessed under the IRIS program.||||||
3,3-Dimethylbenzidine|119-93-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0538
N,N-Dimethylformamide|68-12-2|Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities|mg /m<sup>3</sup>|3x10<sup>-2</sup>|LOAEL (HEC)|7.9|Medium|0511
3,4-Dimethylphenol||Not Assessed under the IRIS program.||||||
2,6-Dimethylphenol||Not Assessed under the IRIS program.||||||
2,4-Dimethylphenol||Not Assessed under the IRIS program.||||||
4,6-Dinitro-o-cyclohexyl phenol||Not Assessed under the IRIS program.||||||
m-Dinitrobenzene||Not Assessed under the IRIS program.||||||
o-Dinitrobenzene||Not Assessed under the IRIS program.||||||
2,4-Dinitrophenol|51-28-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0152
2,4-Dinitrotoluene|121-14-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0542
2,4-/2,6-Dinitrotoluene mixture||Not Assessed under the IRIS program.||||||
Dinoseb||Not Assessed under the IRIS program.||||||
1,4-Dioxane|123-91-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0326
Diphenamid||Not Assessed under the IRIS program.||||||
Diphenylamine||Not Assessed under the IRIS program.||||||
1,2-Diphenylhydrazine|122-66-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0049
Diquat||Not Assessed under the IRIS program.||||||
Disulfoton||Not Assessed under the IRIS program.||||||
1,4-Dithiane||Not Assessed under the IRIS program.||||||
Diuron||Not Assessed under the IRIS program.||||||
Dodine||Not Assessed under the IRIS program.||||||
Endosulfan||Not Assessed under the IRIS program.||||||
Endothall||Not Assessed under the IRIS program.||||||
Endrin||Not Assessed under the IRIS program.||||||
Epichlorohydrin|106-89-8|Changes in the nasal turbinates|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|0.36|Medium|0050
1,2-Epoxybutane (EBU)|106-88-7|Degenerative lesions of the nasal cavity|mg /m<sup>3</sup>|2x10<sup>-2</sup>|LOAEL (HEC)|4.8|Medium|0630
Ethephon||Not Assessed under the IRIS program.||||||
Ethion||Not Assessed under the IRIS program.||||||
2-Ethoxyethanol|110-80-5|Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin|mg /m<sup>3</sup>|2x10<sup>-1</sup>|NOAEL (HEC)|68|Medium|0513
Ethyl acetate||Not Assessed under the IRIS program.||||||
Ethyl carbamate|51-79-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0629
Ethyl chloride|75-00-3|Delayed fetal ossification|mg /m<sup>3</sup>|1x10<sup>1<7sup>|NOAEL (HEC)|4000|Medium|0523
S-Ethyl dipropylthiocarbamate (EPTC)||Not Assessed under the IRIS program.||||||
Ethyl ether||Not Assessed under the IRIS program.||||||
Ethyl p-nitrophenyl phenylphosphorothioate (EPN)||Not Assessed under the IRIS program.||||||
Ethylbenzene|100-41-4|Developmental toxicity|mg /m<sup>3</sup>|1|NOAEL (HEC)|434|Low|0051
Ethylene diamine|107-15-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0528
Ethylene glycol||Not Assessed under the IRIS program.||||||
Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)|111-76-2|Hemosiderin deposition in the liver|mg /m<sup>3</sup>|1.6|BMCL (HEC)|16|Medium/High|0500
Ethylene thiourea (ETU)||Not Assessed under the IRIS program.||||||
Ethyleneimine|151-56-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0631
Ethylphthalyl ethylglycolate (EPEG)||Not Assessed under the IRIS program.||||||
Express||Not Assessed under the IRIS program.||||||
Fenamiphos||Not Assessed under the IRIS program.||||||
Fluometuron||Not Assessed under the IRIS program.||||||
Fluoranthene||Not Assessed under the IRIS program.||||||
Fluorene||Not Assessed under the IRIS program.||||||
Fluorine (soluble fluoride)||Not Assessed under the IRIS program.||||||
Fluridone||Not Assessed under the IRIS program.||||||
Flurprimidol||Not Assessed under the IRIS program.||||||
Flutolanil||Not Assessed under the IRIS program.||||||
Fluvalinate||Not Assessed under the IRIS program.||||||
Folpet||Not Assessed under the IRIS program.||||||
Fomesafen||Not Assessed under the IRIS program.||||||
Fonofos||Not Assessed under the IRIS program.||||||
Formaldehyde||Not Assessed under the IRIS program.||||||
Formic acid||Not Assessed under the IRIS program.||||||
Fosetyl-al||Not Assessed under the IRIS program.||||||
Furan||Not Assessed under the IRIS program.||||||
Furfural||Not Assessed under the IRIS program.||||||
Furmecyclox||Not Assessed under the IRIS program.||||||
Glufosinate-ammonium||Not Assessed under the IRIS program.||||||
Glycidaldehyde||Not Assessed under the IRIS program.||||||
Glyphosate||Not Assessed under the IRIS program.||||||
Haloxyfop-methyl||Not Assessed under the IRIS program.||||||
Harmony||Not Assessed under the IRIS program.||||||
Heptachlor||Not Assessed under the IRIS program.||||||
Heptachlor epoxide||Not Assessed under the IRIS program.||||||
n-Heptane||Not Assessed under the IRIS program.||||||
Hexabromobenzene||Not Assessed under the IRIS program.||||||
Hexabromodiphenyl ether||Not Assessed under the IRIS program.||||||
2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)|68631-49-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1009
Hexachlorobenzene|118-74-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0374
Hexachlorobutadiene||Not Assessed under the IRIS program.||||||
alpha-Hexachlorocyclohexane (alpha-HCH)||Not Assessed under the IRIS program.||||||
beta-Hexachlorocyclohexane (beta-HCH)||Not Assessed under the IRIS program.||||||
delta-Hexachlorocyclohexane (delta-HCH)||Not Assessed under the IRIS program.||||||
epsilon-Hexachlorocyclohexane (epsilon-HC)||Not Assessed under the IRIS program.||||||
gamma-Hexachlorocyclohexane (gamma-HCH)||Not Assessed under the IRIS program.||||||
technical Hexachlorocyclohexane (t-HCH)||Not Assessed under the IRIS program.||||||
Hexachlorocyclopentadiene (HCCPD)|77-47-4|Suppurative inflammation of the nose|mg /m<sup>3</sup>|2x10<sup>-4</sup>|NOAEL (HEC)|0.024|Medium|0059
Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD||Not Assessed under the IRIS program.||||||
Hexachloroethane|67-72-1|Neurotoxicity (tremors and ruffled pelt)|mg /m<sup>3</sup>|3x10<sup>-2</sup>|NOAEL (HEC)|83|Low|0167
Hexachlorophene||Not Assessed under the IRIS program.||||||
Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)||Not Assessed under the IRIS program.||||||
1,6-Hexamethylene diisocyanate||Not Assessed under the IRIS program.||||||
n-Hexane||Not Assessed under the IRIS program.||||||
2-Hexanone||Not Assessed under the IRIS program.||||||
Hexazinone||Not Assessed under the IRIS program.||||||
Hydrazine/Hydrazine sulfate||Not Assessed under the IRIS program.||||||
Hydrogen Cyanide and Cyanide Salts||Not Assessed under the IRIS program.||||||
Hydrogen chloride||Not Assessed under the IRIS program.||||||
Hydrogen sulfide||Not Assessed under the IRIS program.||||||
Hydroquinone||Not Assessed under the IRIS program.||||||
Imazalil||Not Assessed under the IRIS program.||||||
Imazaquin||Not Assessed under the IRIS program.||||||
Indeno[1,2,3-cd]pyrene||Not Assessed under the IRIS program.||||||
Iprodione||Not Assessed under the IRIS program.||||||
Isobutyl alcohol||Not Assessed under the IRIS program.||||||
Isophorone||Not Assessed under the IRIS program.||||||
Isopropalin||Not Assessed under the IRIS program.||||||
Isopropyl methyl phosphonic acid (IMPA)||Not Assessed under the IRIS program.||||||
Isoxaben||Not Assessed under the IRIS program.||||||
Lactofen||Not Assessed under the IRIS program.||||||
Lead and compounds (inorganic)||Not Assessed under the IRIS program.||||||
d-Limonene||Not Assessed under the IRIS program.||||||
Linuron||Not Assessed under the IRIS program.||||||
Londax||Not Assessed under the IRIS program.||||||
Malathion||Not Assessed under the IRIS program.||||||
Maleic anhydride||Not Assessed under the IRIS program.||||||
Maleic hydrazide||Not Assessed under the IRIS program.||||||
Maneb||Not Assessed under the IRIS program.||||||
Manganese||Not Assessed under the IRIS program.||||||
Mepiquat chloride||Not Assessed under the IRIS program.||||||
Mercuric chloride (HgCl2)||Not Assessed under the IRIS program.||||||
Mercury, elemental||Not Assessed under the IRIS program.||||||
Merphos||Not Assessed under the IRIS program.||||||
Merphos oxide||Not Assessed under the IRIS program.||||||
Metalaxyl||Not Assessed under the IRIS program.||||||
Methacrylonitrile||Not Assessed under the IRIS program.||||||
Methamidophos||Not Assessed under the IRIS program.||||||
Methanol||Not Assessed under the IRIS program.||||||
Methidathion||Not Assessed under the IRIS program.||||||
Methomyl||Not Assessed under the IRIS program.||||||
Methoxychlor||Not Assessed under the IRIS program.||||||
2-Methoxyethanol||Not Assessed under the IRIS program.||||||
Methyl acrylate||Not Assessed under the IRIS program.||||||
Methyl chloride||Not Assessed under the IRIS program.||||||
Methyl chlorocarbonate||Not Assessed under the IRIS program.||||||
Methyl ethyl ketone (MEK)||Not Assessed under the IRIS program.||||||
Methyl iodide||Not Assessed under the IRIS program.||||||
Methyl isobutyl ketone (MIBK)||Not Assessed under the IRIS program.||||||
Methyl isocyanate||Not Assessed under the IRIS program.||||||
Methyl methacrylate||Not Assessed under the IRIS program.||||||
Methyl parathion||Not Assessed under the IRIS program.||||||
Methyl tert-butyl ether (MTBE)||Not Assessed under the IRIS program.||||||
4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)||Not Assessed under the IRIS program.||||||
2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)||Not Assessed under the IRIS program.||||||
2-Methyl-4-chlorophenoxyacetic acid (MCPA)||Not Assessed under the IRIS program.||||||
Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)||Not Assessed under the IRIS program.||||||
4,4'-Methylene bis(N,N'-dimethyl)aniline||Not Assessed under the IRIS program.||||||
Methylmercury (MeHg)||Not Assessed under the IRIS program.||||||
2-Methylnaphthalene||Not Assessed under the IRIS program.||||||
4-Methylphenol||Not Assessed under the IRIS program.||||||
3-Methylphenol||Not Assessed under the IRIS program.||||||
2-Methylphenol||Not Assessed under the IRIS program.||||||
Metolachlor||Not Assessed under the IRIS program.||||||
Metribuzin||Not Assessed under the IRIS program.||||||
Mirex||Not Assessed under the IRIS program.||||||
Molinate||Not Assessed under the IRIS program.||||||
Molybdenum||Not Assessed under the IRIS program.||||||
Monochloramine||Not Assessed under the IRIS program.||||||
Naled||Not Assessed under the IRIS program.||||||
Naphthalene||Not Assessed under the IRIS program.||||||
Napropamide||Not Assessed under the IRIS program.||||||
Nickel carbonyl||Not Assessed under the IRIS program.||||||
Nickel refinery dust||Not Assessed under the IRIS program.||||||
Nickel subsulfide||Not Assessed under the IRIS program.||||||
Nickel, soluble salts||Not Assessed under the IRIS program.||||||
Nitrapyrin||Not Assessed under the IRIS program.||||||
Nitrate||Not Assessed under the IRIS program.||||||
Nitric oxide||Not Assessed under the IRIS program.||||||
Nitrite||Not Assessed under the IRIS program.||||||
Nitrobenzene||Not Assessed under the IRIS program.||||||
Nitrogen dioxide||Not Assessed under the IRIS program.||||||
Nitroguanidine||Not Assessed under the IRIS program.||||||
p-Nitrophenol||Not Assessed under the IRIS program.||||||
2-Nitropropane||Not Assessed under the IRIS program.||||||
N-Nitroso-N-methylethylamine||Not Assessed under the IRIS program.||||||
N-Nitroso-di-n-butylamine||Not Assessed under the IRIS program.||||||
N-Nitrosodi-N-propylamine||Not Assessed under the IRIS program.||||||
N-Nitrosodiethanolamine||Not Assessed under the IRIS program.||||||
N-Nitrosodiethylamine||Not Assessed under the IRIS program.||||||
N-Nitrosodimethylamine||Not Assessed under the IRIS program.||||||
N-Nitrosodiphenylamine||Not Assessed under the IRIS program.||||||
N-Nitrosopyrrolidine||Not Assessed under the IRIS program.||||||
Nonabromodiphenyl ether||Not Assessed under the IRIS program.||||||
Norflurazon||Not Assessed under the IRIS program.||||||
NuStar||Not Assessed under the IRIS program.||||||
Octabromodiphenyl ether||Not Assessed under the IRIS program.||||||
Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)||Not Assessed under the IRIS program.||||||
Oryzalin||Not Assessed under the IRIS program.||||||
Oxadiazon||Not Assessed under the IRIS program.||||||
Oxamyl||Not Assessed under the IRIS program.||||||
Oxyfluorfen||Not Assessed under the IRIS program.||||||
Paclobutrazol||Not Assessed under the IRIS program.||||||
Paraquat||Not Assessed under the IRIS program.||||||
Parathion||Not Assessed under the IRIS program.||||||
Pendimethalin||Not Assessed under the IRIS program.||||||
Pentabromodiphenyl ether||Not Assessed under the IRIS program.||||||
2,2',4,4',5-Pentabromodiphenyl ether (BDE-99)||Not Assessed under the IRIS program.||||||
Pentachlorobenzene||Not Assessed under the IRIS program.||||||
Pentachlorocyclopentadiene||Not Assessed under the IRIS program.||||||
Pentachloronitrobenzene (PCNB)||Not Assessed under the IRIS program.||||||
Pentachlorophenol||Not Assessed under the IRIS program.||||||
Pentafluoroethane||Not Assessed under the IRIS program.||||||
Perchlorate (ClO4) and Perchlorate Salts||Not Assessed under the IRIS program.||||||
Permethrin||Not Assessed under the IRIS program.||||||
Phenanthrene||Not Assessed under the IRIS program.||||||
Phenmedipham||Not Assessed under the IRIS program.||||||
Phenol||Not Assessed under the IRIS program.||||||
m-Phenylenediamine||Not Assessed under the IRIS program.||||||
Phenylmercuric acetate||Not Assessed under the IRIS program.||||||
Phosalone||Not Assessed under the IRIS program.||||||
Phosgene||Not Assessed under the IRIS program.||||||
Phosmet||Not Assessed under the IRIS program.||||||
Phosphine||Not Assessed under the IRIS program.||||||
Phosphoric acid||Not Assessed under the IRIS program.||||||
Phthalic anhydride||Not Assessed under the IRIS program.||||||
Picloram||Not Assessed under the IRIS program.||||||
Pirimiphos-methyl||Not Assessed under the IRIS program.||||||
Polychlorinated biphenyls (PCBs)||Not Assessed under the IRIS program.||||||
Potassium cyanide||Not Assessed under the IRIS program.||||||
Potassium silver cyanide||Not Assessed under the IRIS program.||||||
Prochloraz||Not Assessed under the IRIS program.||||||
Prometon||Not Assessed under the IRIS program.||||||
Prometryn||Not Assessed under the IRIS program.||||||
Pronamide||Not Assessed under the IRIS program.||||||
Propachlor||Not Assessed under the IRIS program.||||||
Propanil||Not Assessed under the IRIS program.||||||
Propargite||Not Assessed under the IRIS program.||||||
Propargyl alcohol||Not Assessed under the IRIS program.||||||
Propazine||Not Assessed under the IRIS program.||||||
Propham||Not Assessed under the IRIS program.||||||
Propiconazole||Not Assessed under the IRIS program.||||||
beta-Propiolactone||Not Assessed under the IRIS program.||||||
Propionaldehyde||Not Assessed under the IRIS program.||||||
Propylene glycol||Not Assessed under the IRIS program.||||||
Propylene glycol monoethyl ether||Not Assessed under the IRIS program.||||||
Propylene glycol monomethyl ether (PGME)||Not Assessed under the IRIS program.||||||
Propylene oxide||Not Assessed under the IRIS program.||||||
Propyleneimine||Not Assessed under the IRIS program.||||||
Pursuit||Not Assessed under the IRIS program.||||||
Pydrin||Not Assessed under the IRIS program.||||||
Pyrene||Not Assessed under the IRIS program.||||||
Pyridine||Not Assessed under the IRIS program.||||||
Quinalphos||Not Assessed under the IRIS program.||||||
Quinoline||Not Assessed under the IRIS program.||||||
Quinone||Not Assessed under the IRIS program.||||||
Radium 226,228||Not Assessed under the IRIS program.||||||
Radon 222||Not Assessed under the IRIS program.||||||
Refractory ceramic fibers||Not Assessed under the IRIS program.||||||
Resmethrin||Not Assessed under the IRIS program.||||||
Rotenone||Not Assessed under the IRIS program.||||||
Savey||Not Assessed under the IRIS program.||||||
Selenious acid||Not Assessed under the IRIS program.||||||
Selenium and Compounds||Not Assessed under the IRIS program.||||||
Selenium sulfide||Not Assessed under the IRIS program.||||||
Selenourea||Not Assessed under the IRIS program.||||||
Sethoxydim||Not Assessed under the IRIS program.||||||
Silver||Not Assessed under the IRIS program.||||||
Silver cyanide||Not Assessed under the IRIS program.||||||
Simazine||Not Assessed under the IRIS program.||||||
Sodium azide||Not Assessed under the IRIS program.||||||
Sodium cyanide||Not Assessed under the IRIS program.||||||
Sodium diethyldithiocarbamate||Not Assessed under the IRIS program.||||||
Sodium fluoroacetate||Not Assessed under the IRIS program.||||||
Strontium||Not Assessed under the IRIS program.||||||
Strychnine||Not Assessed under the IRIS program.||||||
Styrene||Not Assessed under the IRIS program.||||||
Systhane||Not Assessed under the IRIS program.||||||
Tebuthiuron||Not Assessed under the IRIS program.||||||
Terbacil||Not Assessed under the IRIS program.||||||
Terbutryn||Not Assessed under the IRIS program.||||||
Tetrabromodiphenyl ether||Not Assessed under the IRIS program.||||||
2,2',4,4'-Tetrabromodiphenyl ether (BDE-47)||Not Assessed under the IRIS program.||||||
1,2,4,5-Tetrachlorobenzene||Not Assessed under the IRIS program.||||||
Tetrachlorocyclopentadiene||Not Assessed under the IRIS program.||||||
2,3,7,8-Tetrachlorodibenzo-p-dioxin||Not Assessed under the IRIS program.||||||
1,1,1,2-Tetrachloroethane||Not Assessed under the IRIS program.||||||
1,1,2,2-Tetrachloroethane||Not Assessed under the IRIS program.||||||
Tetrachloroethylene||Not Assessed under the IRIS program.||||||
2,3,4,6-Tetrachlorophenol||Not Assessed under the IRIS program.||||||
Tetrachlorovinphos||Not Assessed under the IRIS program.||||||
Tetraethyl lead||Not Assessed under the IRIS program.||||||
Tetraethyldithiopyrophosphate||Not Assessed under the IRIS program.||||||
1,1,1,2-Tetrafluoroethane||Not Assessed under the IRIS program.||||||
Tetrahydrofuran||Not Assessed under the IRIS program.||||||
Thallium (I), soluble salts||Not Assessed under the IRIS program.||||||
Thallium acetate||Not Assessed under the IRIS program.||||||
Thallium carbonate||Not Assessed under the IRIS program.||||||
Thallium chloride||Not Assessed under the IRIS program.||||||
Thallium nitrate||Not Assessed under the IRIS program.||||||
Thallium oxide||Not Assessed under the IRIS program.||||||
Thallium selenite||Not Assessed under the IRIS program.||||||
Thallium(I) sulfate||Not Assessed under the IRIS program.||||||
Thiobencarb||Not Assessed under the IRIS program.||||||
Thiophanate-methyl||Not Assessed under the IRIS program.||||||
Thiram||Not Assessed under the IRIS program.||||||
Toluene||Not Assessed under the IRIS program.||||||
2,4-/2,6-Toluene diisocyanate mixture (TDI)||Not Assessed under the IRIS program.||||||
Toxaphene||Not Assessed under the IRIS program.||||||
Tralomethrin||Not Assessed under the IRIS program.||||||
Triallate||Not Assessed under the IRIS program.||||||
Triasulfuron||Not Assessed under the IRIS program.||||||
1,2,4-Tribromobenzene||Not Assessed under the IRIS program.||||||
Tribromochloromethane||Not Assessed under the IRIS program.||||||
Tribromodiphenyl ether||Not Assessed under the IRIS program.||||||
Tributyltin oxide (TBTO)||Not Assessed under the IRIS program.||||||
1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)||Not Assessed under the IRIS program.||||||
Trichloroacetic acid||Not Assessed under the IRIS program.||||||
1,2,4-Trichlorobenzene||Not Assessed under the IRIS program.||||||
Trichlorocyclopentadiene||Not Assessed under the IRIS program.||||||
1,1,2-Trichloroethane||Not Assessed under the IRIS program.||||||
1,1,1-Trichloroethane||Not Assessed under the IRIS program.||||||
Trichloroethylene||Not Assessed under the IRIS program.||||||
Trichlorofluoromethane||Not Assessed under the IRIS program.||||||
2,4,5-Trichlorophenol||Not Assessed under the IRIS program.||||||
2,4,6-Trichlorophenol||Not Assessed under the IRIS program.||||||
2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)||Not Assessed under the IRIS program.||||||
2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)||Not Assessed under the IRIS program.||||||
1,1,2-Trichloropropane||Not Assessed under the IRIS program.||||||
1,2,3-Trichloropropane||Not Assessed under the IRIS program.||||||
Tricresol||Not Assessed under the IRIS program.||||||
Tridiphane||Not Assessed under the IRIS program.||||||
Triethylamine||Not Assessed under the IRIS program.||||||
Triethylene glycol monobutyl ether||Not Assessed under the IRIS program.||||||
Triethylene glycol monoethyl ether||Not Assessed under the IRIS program.||||||
Trifluralin||Not Assessed under the IRIS program.||||||
2,2,4-Trimethylpentane||Not Assessed under the IRIS program.||||||
1,3,5-Trinitrobenzene||Not Assessed under the IRIS program.||||||
2,4,6-Trinitrotoluene (TNT)||Not Assessed under the IRIS program.||||||
Uranium, natural||Not Assessed under the IRIS program.||||||
Uranium, soluble salts||Not Assessed under the IRIS program.||||||
Urea||Not Assessed under the IRIS program.||||||
Vanadium pentoxide||Not Assessed under the IRIS program.||||||
Vernam||Not Assessed under the IRIS program.||||||
Vinclozolin||Not Assessed under the IRIS program.||||||
Vinyl acetate||Not Assessed under the IRIS program.||||||
Vinyl bromide||Not Assessed under the IRIS program.||||||
Vinyl chloride||Not Assessed under the IRIS program.||||||
Warfarin||Not Assessed under the IRIS program.||||||
White phosphorus||Not Assessed under the IRIS program.||||||
Xylenes||Not Assessed under the IRIS program.||||||
Zinc and Compounds||Not Assessed under the IRIS program.||||||
Zinc cyanide||Not Assessed under the IRIS program.||||||
Zinc phosphide||Not Assessed under the IRIS program.||||||
Zineb||Not Assessed under the IRIS program.||||||
</t2b>
 
===Inhalation unit risks===
 
<t2b index = "Substance,Observation type" locations = "CASRN,Precursor Effect/ Tumor Type,Extrapolation Method,Unit,Inhalation unit risks,Study Route,IRIS identifier" unit = "per µg /m<sup>3</sup>">
Acenaphthene|83-32-9|Not Assessed under the IRIS program.|||||
Acenaphthylene|208-96-8|Not Assessed under the IRIS program.|||||
Acephate|30560-19-1|Not Assessed under the IRIS program.|||||
Acetaldehyde|75-07-0|Nasal squamous cell carcinoma or adenocarcinoma|Linearized multistage-variable exposure input form (extra risk) |per µg/m<sup>3</sup>|2.2x10-6|Inhalation|
Acetochlor|34256-82-1|Not Assessed under the IRIS program.|||||
Acetone|67-64-1|Not Assessed under the IRIS program.|||||
Acetonitrile|75-05-8|Not Assessed under the IRIS program.|||||
Acetophenone|98-86-2|Not Assessed under the IRIS program.|||||
Acetyl chloride|75-36-5|Not Assessed under the IRIS program.|||||
Acifluorfen, sodium|62476-59-9|Not Assessed under the IRIS program.|||||
Acrolein|107-02-8|Not Assessed under the IRIS program.|||||
Acrylamide|79-06-1|thyroid tumors and tunica vaginalis mesotheliomas|Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.|per µg /m<sup>3</sup>|1x10-4|Oral, drinking water|
Acrylic acid|79-10-7|Not Assessed under the IRIS program.|||||
Acrylonitrile|107-13-1|Respiratory cancer|Average relative risk||6.8x10-5|Inhalation|
Adiponitrile|111-69-3|Not Assessed under the IRIS program.|||||
Alachlor|15972-60-8|Not Assessed under the IRIS program.|||||
Alar|1596-84-5|Not Assessed under the IRIS program.|||||
Aldicarb|116-06-3|Not Assessed under the IRIS program.|||||
Aldicarb sulfone|1646-88-4|Not Assessed under the IRIS program.|||||
Aldrin|309-00-2|Liver carcinoma|Linearized multistage procedure, extra risk|4.9x10-3|Oral, Diet|
Ally|74223-64-6|Not Assessed under the IRIS program.|||||
Allyl alcohol|107-18-6|Not Assessed under the IRIS program.|||||
Allyl chloride|107-05-1|Not Assessed under the IRIS program.|||||
Aluminum phosphide|20859-73-8|Not Assessed under the IRIS program.|||||
Amdro|67485-29-4|Not Assessed under the IRIS program.|||||
Ametryn|834-12-8|Not Assessed under the IRIS program.|||||
4-Aminopyridine|504-24-5|Not Assessed under the IRIS program.|||||
Amitraz|33089-61-1|Not Assessed under the IRIS program.|||||
Ammonia|7664-41-7|Not Assessed under the IRIS program.|||||
Ammonium acetate|631-61-8|Not Assessed under the IRIS program.|||||
Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program.|||||
Ammonium sulfamate|7773-06-0|Not Assessed under the IRIS program.|||||
Aniline|62-53-3|Not Assessed under the IRIS program.|||||
ortho-Anisidine|90-04-0|Not Assessed under the IRIS program.|||||
Anthracene|120-12-7|Not Assessed under the IRIS program.|||||
Antimony|7440-36-0|Not Assessed under the IRIS program.|||||
Antimony trioxide|1309-64-4|Not Assessed under the IRIS program.|||||
Apollo|74115-24-5|Not Assessed under the IRIS program.|||||
Aramite|140-57-8|Neoplastic liver nodules and carcinomas|Linearized multistage procedure, extra risk|per µg/m<sup>3</sup>|7.1x10-6|Oral, Diet|
Aroclor 1016|12674-11-2|Not Assessed under the IRIS program.|||||
Aroclor 1248|12672-29-6|Not Assessed under the IRIS program.|||||
Aroclor 1254|11097-69-1|Not Assessed under the IRIS program.|||||
Arsenic, inorganic|7440-38-2|Lung cancer|Absolute-risk linear model|per µg/m<sup>3</sup>|4.3x10-3|Inhalation, Occupational exposure|
Arsine|7784-42-1|Not Assessed under the IRIS program.|||||
Asbestos|1332-21-4|Lung cancer and mesothelioma Additive risk of lung cancer and mesothelioma, using relative risk model for lung cancer and absolute risk model for mesothelioma|per f/mL|2.3x10-1|Inhalation, Occupational exposure|
Assure|76578-14-8|Not Assessed under the IRIS program.|||||
Asulam|3337-71-1|Not Assessed under the IRIS program.|||||
Atrazine|1912-24-9|Not Assessed under the IRIS program.|||||
Avermectin B1|65195-55-3|Not Assessed under the IRIS program.|||||
Azobenzene|103-33-3|Abdominal cavity sarcomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.1x10-5|Oral, Diet|
Barium and Compounds|7440-39-3|Not Assessed under the IRIS program.|||||
Barium cyanide|542-62-1|Not Assessed under the IRIS program.|||||
Baygon|114-26-1|Not Assessed under the IRIS program.|||||
Bayleton|43121-43-3|Not Assessed under the IRIS program.|||||
Baythroid|68359-37-5|Not Assessed under the IRIS program.|||||
Benefin|1861-40-1|Not Assessed under the IRIS program.|||||
Benomyl|17804-35-2|Not Assessed under the IRIS program.|||||
Bentazon (Basagran)|25057-89-0|Not Assessed under the IRIS program.|||||
Benz[a]anthracene|56-55-3|Not Assessed under the IRIS program.|||||
Benzaldehyde|100-52-7|Not Assessed under the IRIS program.|||||
Benzene|71-43-2|Leukemia|Low-dose linearity utilizing maximum likelihood estimates|per µg /m<sup>3</sup>|2.2x10-6|Inhalation|
Benzene|71-43-2|Leukemia|Low-dose linearity utilizing maximum likelihood estimates|per µg /m<sup>3</sup>|7.8x10-6|Inhalation|
Benzidine|92-87-5|Bladder tumors|One-hit with time factor, extra risk|per µg /m<sup>3</sup>|6.7x10-2|Inhalation, Occupational exposure|
Benzo[a]pyrene (BaP)|50-32-8|Not Assessed under the IRIS program.|||||
Benzo[b]fluoranthene|205-99-2|Not Assessed under the IRIS program.|||||
Benzo[g,h,i]perylene|191-24-2|Not Assessed under the IRIS program.|||||
Benzo[k]fluoranthene|207-08-9|Not Assessed under the IRIS program.|||||
Benzoic acid|65-85-0|Not Assessed under the IRIS program.|||||
Benzotrichloride|98-07-7|Not Assessed under the IRIS program.|||||
Benzyl chloride|100-44-7|Not Assessed under the IRIS program.|||||
Beryllium and compounds|7440-41-7|Lung cancer|Relative risk|per µg /m<sup>3</sup>|2.4x10-3|Inhalation, Occupational exposure|
Bidrin|141-66-2|Not Assessed under the IRIS program.|||||
Biphenthrin|82657-04-3|Not Assessed under the IRIS program.|||||
1,1-Biphenyl|92-52-4|Not Assessed under the IRIS program.|||||
Bis(2-chloro-1-methylethyl) ether|108-60-1|Not Assessed under the IRIS program.|||||
Bis(2-chloroethoxy)methane|111-91-1|Not Assessed under the IRIS program.|||||
Bis(chloroethyl)ether (BCEE)|111-44-4|Hepatomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.3x10-4|Oral, Gavage followed by diet|
Bis(chloromethyl)ether (BCME)|542-88-1|Respiratory tract tumors Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|6.2x10-2|Inhalation|
Bisphenol A.|80-05-7|Not Assessed under the IRIS program.|||||
Boron and Compounds|7440-42-8|Not Assessed under the IRIS program.|||||
Bromate|15541-45-4|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Brominated dibenzofurans|NA|Not Assessed under the IRIS program.|||||
Bromobenzene|108-86-1|Not Assessed under the IRIS program.|||||
Bromochloromethane|74-97-5|Not Assessed under the IRIS program.|||||
Bromodichloromethane|75-27-4|Not Assessed under the IRIS program.|||||
p-Bromodiphenyl ether|101-55-3|Not Assessed under the IRIS program.|||||
Bromoform|75-25-2|Neoplastic lesions in the large intestine|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.1x10-6|Oral, Gavage in corn oil|
Bromomethane|74-83-9|Not Assessed under the IRIS program.|||||
Bromotrichloromethane|75-62-7|Not Assessed under the IRIS program.|||||
Bromoxynil|1689-84-5|Not Assessed under the IRIS program.|||||
Bromoxynil octanoate|1689-99-2|Not Assessed under the IRIS program.|||||
1,3-Butadiene|106-99-0|Leukemia|Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied.|per µg /m<sup>3</sup>|3x10-5 per|Inhalation|
n-Butanol|71-36-3|Not Assessed under the IRIS program.|||||
Butyl benzyl phthalate|85-68-7|Not Assessed under the IRIS program.|||||
Butylate|2008-41-5|Not Assessed under the IRIS program.|||||
t-Butylchloride|507-20-0|Not Assessed under the IRIS program.|||||
Butylphthalyl butylglycolate (BPBG)|85-70-1|Not Assessed under the IRIS program.|||||
Cacodylic acid|75-60-5|Not Assessed under the IRIS program.|||||
Cadmium|7440-43-9|Lung, trachea, bronchus cancer deaths|Two stage; only first affected by exposure; extra risk|per µg /m<sup>3</sup>|1.8x10-3|Inhalation, Exposure in the workplace|
Calcium cyanide|592-01-8|Not Assessed under the IRIS program.|||||
Caprolactam|105-60-2|Not Assessed under the IRIS program.|||||
Captafol|2425-06-1|Not Assessed under the IRIS program.|||||
Captan|133-06-2|Not Assessed under the IRIS program.|||||
Carbary|l63-25-2|Not Assessed under the IRIS program.|||||
Carbofuran1|563-66-2|Not Assessed under the IRIS program.|||||
Carbon disulfide|75-15-0|Not Assessed under the IRIS program.|||||
Carbon tetrachloride|56-23-5|Pheochromocytoma|Log-probit model with linear extrapolation from the POD (LEC10).|per µg /m<sup>3</sup>|6x10-6|Inhalation|
Carbonyl sulfide|463-58-1|Not Assessed under the IRIS program.|||||
Carbosulfan|55285-14-8|Not Assessed under the IRIS program.|||||
Carboxin|5234-68-4|Not Assessed under the IRIS program.|||||
Cerium Oxide and Cerium Compounds|1306-38-3|Not Assessed under the IRIS program.|||||
Chloral hydrate|302-17-0|Not Assessed under the IRIS program.|||||
Chloramben|133-90-4|Not Assessed under the IRIS program.|||||
Chlordane (Technical)|12789-03-6|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1x10-4|Oral, Diet|
Chlordecone (Kepone)|143-50-0|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Chlorimuron-ethyl|90982-32-4|Not Assessed under the IRIS program.|||||
Chlorine|7782-50-5|Not Assessed under the IRIS program.|||||
Chlorine cyanide|506-77-4|Not Assessed under the IRIS program.|||||
Chlorine dioxide|10049-04-4|Not Assessed under the IRIS program.|||||
Chlorite (sodium salt)|7758-19-2|Not Assessed under the IRIS program.|||||
1-Chloro-1,1-difluoroethane|75-68-3|Not Assessed under the IRIS program.|||||
2-Chloroacetophenone|532-27-4|Not Assessed under the IRIS program.|||||
p-Chloroaniline|106-47-8|Not Assessed under the IRIS program.|||||
Chlorobenzene|108-90-7|Not Assessed under the IRIS program.|||||
Chlorobenzilate|510-15-6|Not Assessed under the IRIS program.|||||
1-Chlorobutane|109-69-3|Not Assessed under the IRIS program.|||||
2-Chlorobutane|78-86-4|Not Assessed under the IRIS program.|||||
Chlorocyclopentadiene|41851-50-7|Not Assessed under the IRIS program.|||||
Chlorodifluoromethane|75-45-6|Not Assessed under the IRIS program.|||||
Chloroform|67-66-3|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.3x10-5|Oral, Gavage|
Chloromethyl methyl ether (CMME)|107-30-2|Not Assessed under the IRIS program.|||||
beta-Chloronaphthalene|91-58-7|Not Assessed under the IRIS program.|||||
2-Chlorophenol|95-57-8|Not Assessed under the IRIS program.|||||
p-Chlorophenyl methyl sulfide|123-09-1|Not Assessed under the IRIS program.|||||
p-Chlorophenyl methyl sulfone|98-57-7|Not Assessed under the IRIS program.|||||
p-Chlorophenyl methyl sulfoxide|934-73-6|Not Assessed under the IRIS program.|||||
Chloroprene|126-99-8|alveolar/ bronchiolar adenoma or carcinoma; hemangioma/ hemangiosarcoma (all organs); mammary gland adenocarcinoma, carcinoma, or adenoacanthoma; forestomach squamous cell papilloma or carcinoma; hepatocellular adenoma or carcinoma; Harderian gland adenoma or carcinoma; skin sarcoma; and Zymbal's gland carcinoma|Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.|per µg /m<sup>3</sup>|3x10-4|Inhalation|
Chlorothalonil|1897-45-6|Not Assessed under the IRIS program.|||||
o-Chlorotoluene|95-49-8|Not Assessed under the IRIS program.|||||
Chlorpropham|101-21-3|Not Assessed under the IRIS program.|||||
Chlorpyrifos|2921-88-2|Not Assessed under the IRIS program.|||||
Chlorsulfuron|64902-72-3|Not Assessed under the IRIS program.|||||
Chromium(III), insoluble salts|16065-83-1|Not Assessed under the IRIS program.
Chromium(VI)|18540-29-9|Lung cancer|Multistage, extra risk|per µg /m<sup>3</sup>|1.2x10-2|Inhalation, Occupational exposure|||||
Chrysene|218-01-9|Not Assessed under the IRIS program.|||||
Coke oven emissions|8007-45-2|Respiratory cancer|Linearized multistage procedure|per µg /m<sup>3</sup>|6.2x10-4|Inhalation, Occupational|
Copper|7440-50-8|Not Assessed under the IRIS program.|||||
Copper cyanide|544-92-3|Not Assessed under the IRIS program.|||||
Creosote|8001-58-9|Not Assessed under the IRIS program.|||||
Crotonaldehyde|123-73-9|Not Assessed under the IRIS program.|||||
Cumene|98-82-8|Not Assessed under the IRIS program.|||||
Cyanazine|21725-46-2|Not Assessed under the IRIS program.|||||
Cyanide, free|57-12-5|Not Assessed under the IRIS program.|||||
Cyanogen|460-19-5|Not Assessed under the IRIS program.|||||
Cyanogen bromide|506-68-3|Not Assessed under the IRIS program.|||||
Cyclohexane|110-82-7|Not Assessed under the IRIS program.|||||
Cyclohexanone|108-94-1|Not Assessed under the IRIS program.|||||
Cyclohexylamine|108-91-8|Not Assessed under the IRIS program.|||||
Cyhalothrin/Karate|68085-85-8|Not Assessed under the IRIS program.|||||
Cypermethrin|52315-07-8|Not Assessed under the IRIS program.|||||
Cyromazine|66215-27-8|Not Assessed under the IRIS program.|||||
Dacthal|1861-32-1|Not Assessed under the IRIS program.|||||
Dalapon, sodium salt|75-99-0|Not Assessed under the IRIS program.|||||
Danitol|39515-41-8|Not Assessed under the IRIS program.|||||
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Not Assessed under the IRIS program.
Demeton 8065-48-3 Not Assessed under the IRIS program.
Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Not Assessed under the IRIS program.
Di(2-ethylhexyl)adipate 103-23-1 Not Assessed under the IRIS program.
2,4-Diaminotoluene 95-80-7 Not Assessed under the IRIS program.
Diazomethane 334-88-3 Not Assessed under the IRIS program.
Dibenz[a,h]anthracene 53-70-3 Not Assessed under the IRIS program.
Dibenzofuran 132-64-9 Not Assessed under the IRIS program.
1,2-Dibromo-3-chloropropane (DBCP) 96-12-8 Not Assessed under the IRIS program.
1,4-Dibromobenzene 106-37-6 Not Assessed under the IRIS program.
Dibromochloromethane 124-48-1 Not Assessed under the IRIS program.
Dibromodichloromethane 594-18-3 Not Assessed under the IRIS program.
p,p'-Dibromodiphenyl ether 2050-47-7 Not Assessed under the IRIS program.
1,2-Dibromoethane 106-93-4 Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range. 6x10-4 per µg/m3 2
3x10-4 per µg/m3 1
Inhalation
 
Dibutyl phthalate 84-74-2 Not Assessed under the IRIS program.
Dicamba 1918-00-9 Not Assessed under the IRIS program.
Dichloroacetic acid 79-43-6 Information reviewed but value not estimated. Refer to IRIS Summary.
1,3-Dichlorobenzene 541-73-1 Not Assessed under the IRIS program.
1,4-Dichlorobenzene 106-46-7 Not Assessed under the IRIS program.
1,2-Dichlorobenzene 95-50-1 Not Assessed under the IRIS program.
3,3'-Dichlorobenzidine 91-94-1 Not Assessed under the IRIS program.
Dichlorodifluoromethane 75-71-8 Not Assessed under the IRIS program.
p,p'-Dichlorodiphenyl dichloroethane (DDD) 72-54-8 Not Assessed under the IRIS program.
p,p'-Dichlorodiphenyldichloroethylene (DDE) 72-55-9 Not Assessed under the IRIS program.
p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Liver tumors, benign and malignant Linear multistage procedure, extra risk 9.7x10-5 per µg/m3 
Oral,
Diet
1,2-Dichloroethane 107-06-2 Hemangiosarcomas Linearized multistage procedure, extra risk 2.6x10-5 per µg/m3 
Oral,
Gavage
1,1-Dichloroethane 75-34-3 Not Assessed under the IRIS program.
trans-1,2-Dichloroethylene 156-60-5 Not Assessed under the IRIS program.
cis-1,2-Dichloroethylene 156-59-2 Not Assessed under the IRIS program.
1,1-Dichloroethylene (1,1-DCE) 75-35-4 Information reviewed but value not estimated. Refer to IRIS Summary.
Dichloromethane 75-09-2 Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas Multistage model with linear extrapolation from the point of departure (BMDL10). 1x10-8 per µg/m3 
Inhalation
 
2,4-Dichlorophenol 120-83-2 Not Assessed under the IRIS program.
4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) 94-82-6 Not Assessed under the IRIS program.
2,4-Dichlorophenoxyacetic acid (2,4-D) 94-75-7 Not Assessed under the IRIS program.
1,2-Dichloropropane 78-87-5 Not Assessed under the IRIS program.
2,3-Dichloropropanol 616-23-9 Not Assessed under the IRIS program.
1,3-Dichloropropene 542-75-6 Bronchioalveolar adenoma Linearized multistage model, extra risk 4x10-6 per µg/m3 
Inhalation
 
Dichlorvos 62-73-7 Not Assessed under the IRIS program.
Dicofol 115-32-2 Not Assessed under the IRIS program.
Dieldrin 60-57-1 Liver carcinoma Linearized multistage procedure, extra risk 4.6x10-3 per µg/m3 
Oral,
Diet
Diesel engine exhaust NA Information reviewed but value not estimated. Refer to IRIS Summary.
Diethyl phthalate 84-66-2 Not Assessed under the IRIS program.
Diethyl sulfate 64-67-5 Not Assessed under the IRIS program.
Diethyl-p-nitrophenylphosphate 311-45-5 Not Assessed under the IRIS program.
Diethylene glycol dinitrate (DEGDN) 693-21-0 Not Assessed under the IRIS program.
Difenzoquat 43222-48-6 Not Assessed under the IRIS program.
Diflubenzuron 35367-38-5 Not Assessed under the IRIS program.
1,1-Difluoroethane 75-37-6 Not Assessed under the IRIS program.
Diisopropyl methylphosphonate (DIMP) 1445-75-6 Not Assessed under the IRIS program.
Dimethipin 55290-64-7 Not Assessed under the IRIS program.
Dimethoate 60-51-5 Not Assessed under the IRIS program.
Dimethyl phthalate 131-11-3 Not Assessed under the IRIS program.
Dimethyl sulfate 77-78-1 Not Assessed under the IRIS program.
Dimethyl terephthalate (DMT) 120-61-6 Not Assessed under the IRIS program.
Dimethylamine 124-40-3 Not Assessed under the IRIS program.
N-N-Dimethylaniline 121-69-7 Not Assessed under the IRIS program.
3,3-Dimethylbenzidine 119-93-7 Not Assessed under the IRIS program.
N,N-Dimethylformamide 68-12-2 Not Assessed under the IRIS program.
3,4-Dimethylphenol 95-65-8 Not Assessed under the IRIS program.
2,6-Dimethylphenol 576-26-1 Not Assessed under the IRIS program.
2,4-Dimethylphenol 105-67-9 Not Assessed under the IRIS program.
4,6-Dinitro-o-cyclohexyl phenol 131-89-5 Not Assessed under the IRIS program.
m-Dinitrobenzene 99-65-0 Not Assessed under the IRIS program.
o-Dinitrobenzene 528-29-0 Not Assessed under the IRIS program.
2,4-Dinitrophenol 51-28-5 Not Assessed under the IRIS program.
2,4-Dinitrotoluene 121-14-2 Not Assessed under the IRIS program.
2,4-/2,6-Dinitrotoluene mixture NA Not Assessed under the IRIS program.
Dinoseb 88-85-7 Not Assessed under the IRIS program.
1,4-Dioxane 123-91-1 Information reviewed but value not estimated. Refer to IRIS Summary.
Diphenamid 957-51-7 Not Assessed under the IRIS program.
Diphenylamine 122-39-4 Not Assessed under the IRIS program.
1,2-Diphenylhydrazine 122-66-7 Hepatocellular carcinomas and neoplastic liver nodules Linearized multistage procedure, extra risk 2.2x10-4 per µg/m3 
Oral,
Diet
Diquat 85-00-7 Not Assessed under the IRIS program.
Disulfoton 298-04-4 Not Assessed under the IRIS program.
1,4-Dithiane 505-29-3 Not Assessed under the IRIS program.
Diuron 330-54-1 Not Assessed under the IRIS program.
Dodine 2439-10-3 Not Assessed under the IRIS program.
Endosulfan 115-29-7 Not Assessed under the IRIS program.
Endothall 145-73-3 Not Assessed under the IRIS program.
Endrin 72-20-8 Not Assessed under the IRIS program.
Epichlorohydrin 106-89-8 Nasal cavity tumors Linearized multistage procedure, extra risk 1.2x10-6 per µg/m3 
Inhalation
 
1,2-Epoxybutane (EBU) 106-88-7 Not Assessed under the IRIS program.
Ethephon 16672-87-0 Not Assessed under the IRIS program.
Ethion 563-12-2 Not Assessed under the IRIS program.
2-Ethoxyethanol 110-80-5 Not Assessed under the IRIS program.
Ethyl acetate 141-78-6 Not Assessed under the IRIS program.
Ethyl carbamate 51-79-6 Not Assessed under the IRIS program.
Ethyl chloride 75-00-3 Not Assessed under the IRIS program.
S-Ethyl dipropylthiocarbamate (EPTC) 759-94-4 Not Assessed under the IRIS program.
Ethyl ether 60-29-7 Not Assessed under the IRIS program.
Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 Not Assessed under the IRIS program.
Ethylbenzene 100-41-4 Not Assessed under the IRIS program.
Ethylene diamine 107-15-3 Not Assessed under the IRIS program.
Ethylene glycol 107-21-1 Not Assessed under the IRIS program.
Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 Information reviewed but value not estimated. Refer to IRIS Summary.
Ethylene thiourea (ETU) 96-45-7 Not Assessed under the IRIS program.
Ethyleneimine 151-56-4 Not Assessed under the IRIS program.
Ethylphthalyl ethylglycolate (EPEG) 84-72-0 Not Assessed under the IRIS program.
Express 101200-48-0 Not Assessed under the IRIS program.
Fenamiphos 22224-92-6 Not Assessed under the IRIS program.
Fluometuron 2164-17-2 Not Assessed under the IRIS program.
Fluoranthene 206-44-0 Not Assessed under the IRIS program.
Fluorene 86-73-7 Not Assessed under the IRIS program.
Fluorine (soluble fluoride) 7782-41-4 Not Assessed under the IRIS program.
Fluridone 59756-60-4 Not Assessed under the IRIS program.
Flurprimidol 56425-91-3 Not Assessed under the IRIS program.
Flutolanil 66332-96-5 Not Assessed under the IRIS program.
Fluvalinate 69409-94-5 Not Assessed under the IRIS program.
Folpet 133-07-3 Not Assessed under the IRIS program.
Fomesafen 72178-02-0 Not Assessed under the IRIS program.
Fonofos 944-22-9 Not Assessed under the IRIS program.
Formaldehyde 50-00-0 Squamous cell carcinoma Linearized multistage procedure, additional risk 1.3x10-5 per µg/m3 
Inhalation
 
Formic acid 64-18-6 Not Assessed under the IRIS program.
Fosetyl-al 39148-24-8 Not Assessed under the IRIS program.
Furan 110-00-9 Not Assessed under the IRIS program.
Furfural 98-01-1 Not Assessed under the IRIS program.
Furmecyclox 60568-05-0 Not Assessed under the IRIS program.
Glufosinate-ammonium 77182-82-2 Not Assessed under the IRIS program.
Glycidaldehyde 765-34-4 Not Assessed under the IRIS program.
Glyphosate 1071-83-6 Not Assessed under the IRIS program.
Haloxyfop-methyl 69806-40-2 Not Assessed under the IRIS program.
Harmony 79277-27-3 Not Assessed under the IRIS program.
Heptachlor 76-44-8 Hepatocellular carcinomas Linearized multistage procedure, extra risk 1.3x10-3 per µg/m3 
Oral,
Diet
Heptachlor epoxide 1024-57-3 Hepatocellular carcinomas Linearized multistage procedure, extra risk 2.6x10-3 per µg/m3 
Oral,
Diet
n-Heptane 142-82-5 Not Assessed under the IRIS program.
Hexabromobenzene 87-82-1 Not Assessed under the IRIS program.
Hexabromodiphenyl ether 36483-60-0 Not Assessed under the IRIS program.
2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 Not Assessed under the IRIS program.
Hexachlorobenzene 118-74-1 Hepatocellular carcinoma Linearized multistage, extra risk 4.6x10-4 per µg/m3 
Oral,
Diet
Hexachlorobutadiene 87-68-3 Renal tubular adenomas and adenocarcinomas Linearized multistage procedure, extra risk 2.2x10-5 per µg/m3 
Oral,
Diet
alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 Hepatic nodules and hepatocellular carcinomas Linearized multistage procedure, extra risk 1.8x10-3 per µg/m3 
Oral,
Diet
beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 Hepatic nodules and hepatocellular carcinomas Linearized multistage procedure, extra risk 5.3x10-4 per µg/m3 
Oral,
Diet
delta-Hexachlorocyclohexane (delta-HCH) 319-86-8 Not Assessed under the IRIS program.
epsilon-Hexachlorocyclohexane (epsilon-HC) 6108-10-7 Not Assessed under the IRIS program.
gamma-Hexachlorocyclohexane (gamma-HCH) 58-89-9 Not Assessed under the IRIS program.
technical Hexachlorocyclohexane (t-HCH) 608-73-1 Liver nodules and hepatocellular carcinomas Linearized multistage procedure 5.1x10-4 per µg/m3 
Oral,
Diet
Hexachlorocyclopentadiene (HCCPD) 77-47-4 Not Assessed under the IRIS program.
Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) Linearized multistage procedure, extra risk 1.3 per µg/m3 
Oral,
Gavage
Hexachloroethane 67-72-1 Information reviewed but value not estimated. Refer to IRIS Summary.
Hexachlorophene 70-30-4 Not Assessed under the IRIS program.
Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Not Assessed under the IRIS program.
1,6-Hexamethylene diisocyanate 822-06-0 Not Assessed under the IRIS program.
n-Hexane 110-54-3 Not Assessed under the IRIS program.
2-Hexanone 591-78-6 Not Assessed under the IRIS program.
Hexazinone 51235-04-2 Not Assessed under the IRIS program.
Hydrazine/Hydrazine sulfate|302-01-2|Nasal cavity adenoma or adenocarcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|4.9x10-3|Inhalation|
Hydrogen Cyanide and Cyanide Salts Various Not Assessed under the IRIS program.
Hydrogen chloride 7647-01-0 Not Assessed under the IRIS program.
Hydrogen sulfide 7783-06-4 Not Assessed under the IRIS program.
Hydroquinone 123-31-9 Not Assessed under the IRIS program.
Imazalil 35554-44-0 Not Assessed under the IRIS program.
Imazaquin 81335-37-7 Not Assessed under the IRIS program.
Indeno[1,2,3-cd]pyrene 193-39-5 Not Assessed under the IRIS program.
Iprodione 36734-19-7 Not Assessed under the IRIS program.
Isobutyl alcohol 78-83-1 Not Assessed under the IRIS program.
Isophorone 78-59-1 Not Assessed under the IRIS program.
Isopropalin 33820-53-0 Not Assessed under the IRIS program.
Isopropyl methyl phosphonic acid (IMPA) 1832-54-8 Not Assessed under the IRIS program.
Isoxaben 82558-50-7 Not Assessed under the IRIS program.
Lactofen 77501-63-4 Not Assessed under the IRIS program.
Lead and compounds (inorganic) 7439-92-1 Not Assessed under the IRIS program.
d-Limonene 5989-27-5 Not Assessed under the IRIS program.
Linuron 330-55-2 Not Assessed under the IRIS program.
Londax 83055-99-6 Not Assessed under the IRIS program.
Malathion 121-75-5 Not Assessed under the IRIS program.
Maleic anhydride 108-31-6 Not Assessed under the IRIS program.
Maleic hydrazide 123-33-1 Not Assessed under the IRIS program.
Maneb 12427-38-2 Not Assessed under the IRIS program.
Manganese 7439-96-5 Not Assessed under the IRIS program.
Mepiquat chloride 24307-26-4 Not Assessed under the IRIS program.
Mercuric chloride (HgCl2) 7487-94-7 Not Assessed under the IRIS program.
Mercury, elemental 7439-97-6 Not Assessed under the IRIS program.
Merphos 150-50-5 Not Assessed under the IRIS program.
Merphos oxide 78-48-8 Not Assessed under the IRIS program.
Metalaxyl 57837-19-1 Not Assessed under the IRIS program.
Methacrylonitrile 126-98-7 Not Assessed under the IRIS program.
Methamidophos 10265-92-6 Not Assessed under the IRIS program.
Methanol 67-56-1 Not Assessed under the IRIS program.
Methidathion 950-37-8 Not Assessed under the IRIS program.
Methomyl 16752-77-5 Not Assessed under the IRIS program.
Methoxychlor 72-43-5 Not Assessed under the IRIS program.
2-Methoxyethanol 109-86-4 Not Assessed under the IRIS program.
Methyl acrylate 96-33-3 Not Assessed under the IRIS program.
Methyl chloride 74-87-3 Not Assessed under the IRIS program.
Methyl chlorocarbonate 79-22-1 Not Assessed under the IRIS program.
Methyl ethyl ketone (MEK) 78-93-3 Not Assessed under the IRIS program.
Methyl iodide 74-88-4 Not Assessed under the IRIS program.
Methyl isobutyl ketone (MIBK) 108-10-1 Not Assessed under the IRIS program.
Methyl isocyanate 624-83-9 Not Assessed under the IRIS program.
Methyl methacrylate 80-62-6 Not Assessed under the IRIS program.
Methyl parathion 298-00-0 Not Assessed under the IRIS program.
Methyl tert-butyl ether (MTBE) 1634-04-4 Not Assessed under the IRIS program.
4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 Not Assessed under the IRIS program.
2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 Not Assessed under the IRIS program.
2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 Not Assessed under the IRIS program.
Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)|101-68-8|Not Assessed under the IRIS program.|||||
4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 Not Assessed under the IRIS program.
Methylmercury (MeHg) 22967-92-6 Not Assessed under the IRIS program.
2-Methylnaphthalene 91-57-6 Not Assessed under the IRIS program.
2-Methylphenol 95-48-7 Not Assessed under the IRIS program.
4-Methylphenol 106-44-5 Not Assessed under the IRIS program.
3-Methylphenol 108-39-4 Not Assessed under the IRIS program.
Metolachlor 51218-45-2 Not Assessed under the IRIS program.
Metribuzin 21087-64-9 Not Assessed under the IRIS program.
Mirex 2385-85-5 Not Assessed under the IRIS program.
Molinate 2212-67-1 Not Assessed under the IRIS program.
Molybdenum 7439-98-7 Not Assessed under the IRIS program.
Monochloramine 10599-90-3 Not Assessed under the IRIS program.
Naled 300-76-5 Not Assessed under the IRIS program.
Naphthalene 91-20-3 Information reviewed but value not estimated. Refer to IRIS Summary.
Napropamide 15299-99-7 Not Assessed under the IRIS program.
Nickel carbonyl 13463-39-3 Not Assessed under the IRIS program.
Nickel refinery dust|NA|Lung cancer|Additive and multiplicative|per µg /m<sup>3</sup>|2.4x10-4|Inhalation|
Nickel subsulfide|12035-72-2|Lung cancer|Additive and multiplicative|per µg /m<sup>3</sup>|4.8x10-4|Inhalation|
Nickel, soluble salts NA Not Assessed under the IRIS program.
Nitrapyrin 1929-82-4 Not Assessed under the IRIS program.
Nitrate 14797-55-8 Not Assessed under the IRIS program.
Nitric oxide 10102-43-9 Not Assessed under the IRIS program.
Nitrite 14797-65-0 Not Assessed under the IRIS program.
Nitrobenzene|98-95-3|Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas|Multistage model with linear extrapolation from the POD (LEC10).|per µg /m<sup>3</sup>|4x10-5|Inhalation|
Nitrogen dioxide 10102-44-0 Not Assessed under the IRIS program.
Nitroguanidine 556-88-7 Not Assessed under the IRIS program.
p-Nitrophenol 100-02-7 Not Assessed under the IRIS program.
2-Nitropropane 79-46-9 Not Assessed under the IRIS program.
N-Nitroso-N-methylethylamine 10595-95-6 Not Assessed under the IRIS program.
N-Nitroso-di-n-butylamine|924-16-3|Bladder and esophagus tumors|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.6x10-3|Oral, Drinking water|
N-Nitrosodi-N-propylamine 621-64-7 Not Assessed under the IRIS program.
N-Nitrosodiethanolamine 1116-54-7 Not Assessed under the IRIS program.
N-Nitrosodiethylamine|55-18-5|Liver tumors|Weibull, extra risk|4.3x10-2|Oral, Drinking water
N-Nitrosodimethylamine|62-75-9|Liver tumors|Weibull, extra risk|per µg /m<sup>3</sup>|1.4x10-2|Oral, Drinking water|
N-Nitrosodiphenylamine 86-30-6 Not Assessed under the IRIS program.
N-Nitrosopyrrolidine|930-55-2|Hepatocellular carcinoma and adenoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|6.1x10-4|Oral, Diet|
Nonabromodiphenyl ether 63936-56-1 Not Assessed under the IRIS program.
Norflurazon 27314-13-2 Not Assessed under the IRIS program.
NuStar 85509-19-9 Not Assessed under the IRIS program.
Octabromodiphenyl ether 32536-52-0 Not Assessed under the IRIS program.
Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) 2691-41-0 Not Assessed under the IRIS program.
Oryzalin 19044-88-3 Not Assessed under the IRIS program.
Oxadiazon 19666-30-9 Not Assessed under the IRIS program.
Oxamyl 23135-22-0 Not Assessed under the IRIS program.
Oxyfluorfen 42874-03-3 Not Assessed under the IRIS program.
Paclobutrazol 76738-62-0 Not Assessed under the IRIS program.
Paraquat 1910-42-5 Not Assessed under the IRIS program.
Parathion 56-38-2 Not Assessed under the IRIS program.
Pendimethalin 40487-42-1 Not Assessed under the IRIS program.
Pentabromodiphenyl ether 32534-81-9 Not Assessed under the IRIS program.
2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 Not Assessed under the IRIS program.
Pentachlorobenzene 608-93-5 Not Assessed under the IRIS program.
Pentachlorocyclopentadiene 25329-35-5 Not Assessed under the IRIS program.
Pentachloronitrobenzene (PCNB) 82-68-8 Not Assessed under the IRIS program.
Pentachlorophenol 87-86-5 Not Assessed under the IRIS program.
Pentafluoroethane 354-33-6 Not Assessed under the IRIS program.
Perchlorate (ClO4) and Perchlorate Salts 7790-98-9 Not Assessed under the IRIS program.
Permethrin 52645-53-1 Not Assessed under the IRIS program.
Phenanthrene 85-01-8 Not Assessed under the IRIS program.
Phenmedipham 13684-63-4 Not Assessed under the IRIS program.
Phenol 108-95-2 Not Assessed under the IRIS program.
m-Phenylenediamine 108-45-2 Not Assessed under the IRIS program.
Phenylmercuric acetate 62-38-4 Not Assessed under the IRIS program.
Phosalone 2310-17-0 Not Assessed under the IRIS program.
Phosgene 75-44-5 Not Assessed under the IRIS program.
Phosmet 732-11-6 Not Assessed under the IRIS program.
Phosphine 7803-51-2 Not Assessed under the IRIS program.
Phosphoric acid 7664-38-2 Not Assessed under the IRIS program.
Phthalic anhydride 85-44-9 Not Assessed under the IRIS program.
Picloram 1918-02-1 Not Assessed under the IRIS program.
Pirimiphos-methyl 29232-93-7 Not Assessed under the IRIS program.
Polychlorinated biphenyls (PCBs)|1336-36-3|Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas|Linear extrapolation below LED10s|per µg /m<sup>3</sup>|1x10-4|Oral, Diet|
Potassium cyanide 151-50-8 Not Assessed under the IRIS program.
Potassium silver cyanide 506-61-6 Not Assessed under the IRIS program.
Prochloraz 67747-09-5 Not Assessed under the IRIS program.
Prometon 1610-18-0 Not Assessed under the IRIS program.
Prometryn 7287-19-6 Not Assessed under the IRIS program.
Pronamide 23950-58-5 Not Assessed under the IRIS program.
Propachlor 1918-16-7 Not Assessed under the IRIS program.
Propanil 709-98-8 Not Assessed under the IRIS program.
Propargite 2312-35-8 Not Assessed under the IRIS program.
Propargyl alcohol 107-19-7 Not Assessed under the IRIS program.
Propazine 139-40-2 Not Assessed under the IRIS program.
Propham 122-42-9 Not Assessed under the IRIS program.
Propiconazole 60207-90-1 Not Assessed under the IRIS program.
beta-Propiolactone 57-57-8 Not Assessed under the IRIS program.
Propionaldehyde 123-38-6 Not Assessed under the IRIS program.
Propylene glycol 57-55-6 Not Assessed under the IRIS program.
Propylene glycol monoethyl ether 52125-53-8 Not Assessed under the IRIS program.
Propylene glycol monomethyl ether (PGME) 107-98-2 Not Assessed under the IRIS program.
Propylene oxide|75-56-9|Nasal cavity hemangioma or hemangiosarcoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.7x10-6|Inhalation|
Propyleneimine 75-55-8 Not Assessed under the IRIS program.
Pursuit 81335-77-5 Not Assessed under the IRIS program.
Pydrin 51630-58-1 Not Assessed under the IRIS program.
Pyrene 129-00-0 Not Assessed under the IRIS program.
Pyridine 110-86-1 Not Assessed under the IRIS program.
Quinalphos 13593-03-8 Not Assessed under the IRIS program.
Quinoline 91-22-5 Information reviewed but value not estimated. Refer to IRIS Summary.
Quinone 106-51-4 Not Assessed under the IRIS program.
Radium 226,228 7440-14-4 Not Assessed under the IRIS program.
Radon 222 14859-67-7 Not Assessed under the IRIS program.
Refractory ceramic fibers NA Information reviewed but value not estimated. Refer to IRIS Summary.
Resmethrin 10453-86-8 Not Assessed under the IRIS program.
Rotenone 83-79-4 Not Assessed under the IRIS program.
Savey 78587-05-0 Not Assessed under the IRIS program.
Selenious acid 7783-00-8 Not Assessed under the IRIS program.
Selenium and Compounds 7782-49-2 Not Assessed under the IRIS program.
Selenium sulfide 7446-34-6 Not Assessed under the IRIS program.
Selenourea 630-10-4 Not Assessed under the IRIS program.
Sethoxydim 74051-80-2 Not Assessed under the IRIS program.
Silver 7440-22-4 Not Assessed under the IRIS program.
Silver cyanide 506-64-9 Not Assessed under the IRIS program.
Simazine 122-34-9 Not Assessed under the IRIS program.
Sodium azide 26628-22-8 Not Assessed under the IRIS program.
Sodium cyanide 143-33-9 Not Assessed under the IRIS program.
Sodium diethyldithiocarbamate 148-18-5 Not Assessed under the IRIS program.
Sodium fluoroacetate 62-74-8 Not Assessed under the IRIS program.
Strontium 7440-24-6 Not Assessed under the IRIS program.
Strychnine 57-24-9 Not Assessed under the IRIS program.
Styrene 100-42-5 Not Assessed under the IRIS program.
Systhane 88671-89-0 Not Assessed under the IRIS program.
Tebuthiuron 34014-18-1 Not Assessed under the IRIS program.
Terbacil 5902-51-2 Not Assessed under the IRIS program.
Terbutryn 886-50-0 Not Assessed under the IRIS program.
Tetrabromodiphenyl ether 40088-47-9 Not Assessed under the IRIS program.
2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 Not Assessed under the IRIS program.
1,2,4,5-Tetrachlorobenzene 95-94-3 Not Assessed under the IRIS program.
Tetrachlorocyclopentadiene 695-77-2 Not Assessed under the IRIS program.
1,1,1,2-Tetrachloroethane|630-20-6|Hepatocellular adenoma or carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|7.4x10-6|Oral, Gavage|
1,1,2,2-Tetrachloroethane 79-34-5 Information reviewed but value not estimated. Refer to IRIS Summary.
Tetrachloroethylene 127-18-4 Not Assessed under the IRIS program.
2,3,4,6-Tetrachlorophenol 58-90-2 Not Assessed under the IRIS program.
Tetrachlorovinphos 961-11-5 Not Assessed under the IRIS program.
Tetraethyl lead 78-00-2 Not Assessed under the IRIS program.
Tetraethyldithiopyrophosphate 3689-24-5 Not Assessed under the IRIS program.
1,1,1,2-Tetrafluoroethane 811-97-2 Not Assessed under the IRIS program.
Thallium (I), soluble salts Various Not Assessed under the IRIS program.
Thallium acetate 563-68-8 Not Assessed under the IRIS program.
Thallium carbonate 6533-73-9 Not Assessed under the IRIS program.
Thallium chloride 7791-12-0 Not Assessed under the IRIS program.
Thallium nitrate 10102-45-1 Not Assessed under the IRIS program.
Thallium oxide 1314-32-5 Not Assessed under the IRIS program.
Thallium selenite 12039-52-0 Not Assessed under the IRIS program.
Thallium(I) sulfate 7446-18-6 Not Assessed under the IRIS program.
Thiobencarb 28249-77-6 Not Assessed under the IRIS program.
Thiophanate-methyl 23564-05-8 Not Assessed under the IRIS program.
Thiram 137-26-8 Not Assessed under the IRIS program.
Toluene 108-88-3 Not Assessed under the IRIS program.
2,4-/2,6-Toluene diisocyanate mixture (TDI)|26471-62-5|Not Assessed under the IRIS program.|||||
Toxaphene|8001-35-2|Hepatocellular carcinomas and neoplastic nodules|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.2x10-4|Oral, Diet|
Tralomethrin|66841-25-6|Not Assessed under the IRIS program.|||||
Triallate|2303-17-5|Not Assessed under the IRIS program.|||||
Triasulfuron|82097-50-5|Not Assessed under the IRIS program.|||||
1,2,4-Tribromobenzene|615-54-3|Not Assessed under the IRIS program.|||||
Tribromochloromethane|594-15-0|Not Assessed under the IRIS program.|||||
Tribromodiphenyl ether|49690-94-0|Not Assessed under the IRIS program.|||||
Tributyltin oxide (TBTO)|56-35-9|Not Assessed under the IRIS program.|||||
1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)|76-13-1|Not Assessed under the IRIS program.|||||
Trichloroacetic acid|76-03-9|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
1,2,4-Trichlorobenzene|120-82-1|Not Assessed under the IRIS program.|||||
Trichlorocyclopentadiene|77323-84-3|Not Assessed under the IRIS program.|||||
1,1,2-Trichloroethane|79-00-5|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.6x10-5|Oral, Gavage|
1,1,1-Trichloroethane|71-55-6|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
Trichloroethylene|79-01-6|Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors|Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk|per µg /m<sup>3</sup>|4.1x10-6|Inhalation|
Trichlorofluoromethane|75-69-4|Not Assessed under the IRIS program.|||||
2,4,5-Trichlorophenol|95-95-4|Not Assessed under the IRIS program.|||||
2,4,6-Trichlorophenol|88-06-2|Leukemia|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.1x10-6 |Oral,Diet|
2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)|93-72-1|Not Assessed under the IRIS program.|||||
2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)|93-76-5|Not Assessed under the IRIS program.|||||
1,1,2-Trichloropropane|598-77-6|Not Assessed under the IRIS program.|||||
1,2,3-Trichloropropane|96-18-4|Not Assessed under the IRIS program.|||||
Tricresol|1319-77-3|Not Assessed under the IRIS program.|||||
Tridiphane|58138-08-2|Not Assessed under the IRIS program.|||||
Triethylamine|121-44-8|Not Assessed under the IRIS program.|||||
Triethylene glycol monobutyl ether|143-22-6|Not Assessed under the IRIS program.||||||
Triethylene glycol monoethyl ether|112-50-5|Not Assessed under the IRIS program.|||||
Trifluralin|1582-09-8|Not Assessed under the IRIS program.|||||
2,2,4-Trimethylpentane|540-84-1|Not Assessed under the IRIS program.|||||
1,3,5-Trinitrobenzene|99-35-4|Not Assessed under the IRIS program.|||||
2,4,6-Trinitrotoluene (TNT)|118-96-7|Not Assessed under the IRIS program.|||||
Uranium, natural|7440-61-1|Not Assessed under the IRIS program.|||||
Uranium, soluble salts|NA|Not Assessed under the IRIS program.|||||
Urea|57-13-6|Not Assessed under the IRIS program.|||||
Vanadium pentoxide|1314-62-1|Not Assessed under the IRIS program.|||||
Vernam|1929-77-7|Not Assessed under the IRIS program.|||||
Vinclozolin|50471-44-8|Not Assessed under the IRIS program.|||||
Vinyl acetate|108-05-4|Not Assessed under the IRIS program.|||||
Vinyl bromide|593-60-2Not Assessed under the IRIS program.|||||
Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LMS method|per µg /m<sup>3</sup>|4.4x10-6|Inhalation|
Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LED 10/ linear method|per µg /m<sup>3</sup>|4.4x10-6|Inhalation|
Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LMS method|per µg /m<sup>3</sup>|8.8x10-6|Inhalation|
Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LED 10/ linear method|per µg /m<sup>3</sup>|8.8x10-6|Inhalation|
Warfarin|81-81-2|Not Assessed under the IRIS program.|||||
White phosphorus|7723-14-0|Not Assessed under the IRIS program.|||||
Xylenes|1330-20-7|Not Assessed under the IRIS program.|||||
Zinc and Compounds|7440-66-6|Not Assessed under the IRIS program.|||||
Zinc cyanide|557-21-1|Not Assessed under the IRIS program.|||||
Zinc phosphide|1314-84-7|Not Assessed under the IRIS program.|||||
Zineb|12122-67-7|Not Assessed under the IRIS program.|||||
</t2b>


* [[IRIS/Oral RfDs]]
* [[IRIS/Inhalation RfCs]]
* [[IRIS/Weight-of-Evidence Characterizations]]
* [[IRIS/Inhalation unit risks]]
* [[Template:IRIS links]]


==References==
==References==

Latest revision as of 13:02, 11 March 2014

This page provides a description and a link to a "IRIS" database that provides information needed when modeling exposure levels or performing exposure assessment.

Short description

IRIS is a database of human health effects that may result from exposure to various substances found in the environment. The heart of the IRIS system is its collection of computer files covering individual chemicals. These chemical files contain descriptive and quantitative information in the following categories: a) Oral reference doses and inhalation reference concentrations (RfDs and RfCs, respectively) for chronic noncarcinogenic health effects, b) Hazard identification, oral slope factors, and oral and inhalation unit risks for carcinogenic effects. Database includes over 500 chemicals.

Long description

http://www.nlm.nih.gov/pubs/factsheets/irisfs.html

Link

http://www.epa.gov/iris/

Key words

human health effects, exposure, toxicology, carcinogenity, hazards

Data scrapping

IRIS database is accessible from this link: http://cfpub.epa.gov/ncea/iris/compare.cfm. The critical data can be obtained at once if all substances and all types of data are selected. A result is an html file with several tables from which the data can be scrapped and transformed into a better format. The January 4th, 2012, version was downloaded from IRIS and saved on this page (see the file below). Who could do this?

Reference system in IRIS database. The number (e.g. 0442) refers to the IRIS chemical identifier. 

QuickView
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal  Oral RfDs
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#refinhal Inhalation RfCs
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#woe      Weight-of-Evidence Characterizations
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quaoral  Oral Slope Factors/Drinking Water Unit Risks
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quainhal Inhalation Unit Risks

IRIS Summary 
http://www.epa.gov/iris/subst/0442.htm#reforal
http://www.epa.gov/iris/subst/0442.htm#refinhal
http://www.epa.gov/iris/subst/0442.htm#woe
http://www.epa.gov/iris/subst/0442.htm#quaoral
http://www.epa.gov/iris/subst/0442.htm#quainhal

Toxicological Review (PDF)
http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)

←--#: . Tämähän alkaa olla oikein hyvä! Alla vielä muutamia kommentteja. --Jouni 20:34, 28 June 2012 (EEST) (type: truth; paradigms: science: defence)

  • Tulokset on tässä kirjoitettu muotoon 3.4x10-3. Joko interpret-funktiota on päivitettävä siten, että se ymmärtää tämän, tai sitten kaikki näiden taulukoiden tulokset pitää muuttaa muotoon 3.4e-3 (jonka R ymmärtää oikein, kun käytetään as.numericia). Tuntuu, että interpretin päivitys olisi parempi vaihtoehto.
  • Yksiköt pitäisi muuttaa tietokoneelle ymmärrettäväksi. Vaihtoehtoja: a) Unit conversions -sivulle lisätään kaikki tässä esiintyvät uudet yksiköt, niin että niille saadaan muunnosohjeet (esim. mg /kg-day → mg /kg /d tai per µg /m3 → m3 /µg. b) Kaikki yksiköt tällä sivulla muutetaan tuohon standardimuotoon. Mikä tuntuisi järkevältä?


⇤--#: . Jos jossakin taulukossa joka rivillä on sama yksikkö, koko saraketta ei tarvita vaan riittää yksikön ilmoittaminen osoiterivillä. --Jouni 20:34, 28 June 2012 (EEST) (type: truth; paradigms: science: attack)

⇤--#: . Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä. --Jouni 10:42, 20 June 2012 (EEST) (type: truth; paradigms: science: attack)

⇤--#: . Huomaa, että IRIS identifier on tärkeä. Se löytyy nettilinkeistä (esim. Acenaphthenen QuickView on tämmöinen linkki: http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal ja siitä näkee, että tämän aineen IRIS identifier on 0442. --Jouni 10:42, 20 June 2012 (EEST) (type: truth; paradigms: science: attack)

See also

References


Related files

<mfanonymousfilelist></mfanonymousfilelist>

Retrieved from "https://en.opasnet.org/index.php?title=IRIS&oldid=31668"